Dr Phillip Stricker

Personal Statement

Professor Stricker is a urologist and one of the leading experts in the management and treatment of prostate cancer in Australasia. He is the Director of the St Vincent’s Prostate Cancer Centre, Chairman of the Department of Urology at St Vincent’s Private Hospital and Clinic and the Clinical Director of the Australian Prostate Cancer Research Centre in New South Wales (NSW). He is also a professor and associate professor at numerous recognised Institutions, University of Western Sydney, University of Tasmania, University of NSW and University of Sydney.

His clinical practice is dedicated to the management and treatment of prostate cancer focusing on personalised care. This includes initial consultation, therapy and follow–up of all post treatment side effects including erectile dysfunction and incontinence. In 2006, he commenced the first robotic program using the latest technology (Da Vinci Si) in NSW at St Vincent’s Hospital. He has since performed over 6,500 radical prostatectomy cases, the largest Australasian series; more than 2,000 of which have been performed using the robotic–assisted radio guided surgery. He also has extensive experience in performing high–dose rate brachytherapy (over 1000 cases), low–dose rate brachytherapy (over 1000 cases), designing and managing structured active surveillance programs and transperineal biopsies (over 7000 cases).

He has been one of the Australian pioneers in multiparametric MRI and PSMA–PET scan imaging and introduction of focal therapy using irreversible electroporation–IRE (Nano–Knife) to treat prostate cancer and has performed over 300 cases. He has substantial experience in dealing with impotence and incontinence assessments, urodynamics and treatments including penile prosthesis, sling surgery and artificial urinary sphincter surgery.

Professor Stricker’s area of research focuses on the collection of quality of life data following treatment in order to refine surgical techniques, development and assessment of novel surgical techniques which are less invasive, the utilisation of medical imaging for the detection and evaluation of prostate cancer, and validation of nomograms to influence treatment decisions.

Professor Stricker was the driving force in setting up St Vincent’s Prostate Cancer Clinical Database and Tissue Bank in conjunction with the Garvan Institute, which is currently housed at The Kinghorn Cancer Centre. These resources contain extensive clinical and pathological outcome data and have resulted in a comprehensive scientific and clinical resource that has been acknowledged both nationally and internationally.

Professor Stricker is a Member of the Australian Cancer Network working party that developed guidelines for the Management of Locally advanced and metastatic prostate cancer and PSA Testing. These guidelines have been published and used as evidence–based in publications supported by NH&MRC. Professor Stricker has authored over 200 peer–reviewed publications, has collaborative research partnerships within Australia and globally and has been involved with numerous successful grant funding applications.

Current Positions

Emeritus Fellow, Garvan Institute of Medical Research (2020)

Chairman, Dept. Urology, St Vincent’s Private Hospital and Clinic and HMO St Vincent’s Hospital

Chairman, Urology, Oncology and Prostate Cancer Multidisciplinary Team at St Vincent’s Hospital

Clinical Director, Prostate Cancer Research, The Kinghorn Cancer Centre

Clinical Director, The Australian Prostate Cancer Research Centre – New South Wales

Director, St. Vincent’s Prostate Cancer Centre

Director, Australian Prostate Cancer Collaboration

Conjoint Associate Professor, Department of Surgery, University of New South Wales Australia

Clinical Associate Professor, Sydney Medical School, University of Sydney

Clinical Professor, School of Health Sciences, University of Tasmania

Conjoint Professor, School of Medicine, University of Western Sydney

Tertiary Education

1978 – MBBS (Hons) University of New South Wales Australia

1980 – FRACS Part I

1980 – VQE

1988 – FRACS (Urology) Part II

Clinical Training

1979 – 1981 Junior Residency – St George Hospital

1982 – 1985 General Surgical Training and Fellowship

1986 – 1988 Urological Training and Fellowship

1989 – Visiting Urologist to St Vincent's Hospital, Sydney

1989 – 2001 Visiting Urologist to the Royal Hospital for Women, Sydney

1989 – Visiting Urologist to St Vincent's Private Hospital, Sydney

1989 – 2001 Visiting Urologist to the Royal Hospital for Women, Sydney

1989 – Visiting Urologist to St Luke's Hospital, Sydney

1993 – Consultant Transplant Surgeon to St George Hospital, Sydney

2000 – Conjoint Senior Lecturer University of NSW, Sydney

2004 – Conjoint Associate Professor University of NSW, Sydney

2013 – Clinical Associate Professor Sydney Medical School, Sydney University

2014 – Clinical Professor, School of Health Sciences, University of Tasmania

2016 – Conjoint Professor, School of Medicine, University of Western Sydney

Post–Fellowship Training

• Impotence Surgical Training: Bill Furlow (Nashville), Tom Lue (San Francisco), Steve Wilson (Arkensaw)
• Pelvic Cancer Surgery: – Bill Fair and H Herr (Sloan Kettering, New York), Donald Skinner (U.S.C.), Scott Swanson, Michael Lieber, John Blasko, Joe Oesterling, Peter Scardino, Bertrand Guillaneau (St Vincent's Hospital), Keith Kaye (Perth)
• Incontinence Surgery: – S.Raz (U.C.L.A.) – open surgery – R.Appell (Memphis) – collagen – E. Mcguire and Ann Arbour – slings
• Stone Surgery: –J.Segura (St Vincent's Hospital), EDAP Machine (St Vincent's Hospital), Glen Preminger (St Vincent's Hospital)
• Ablatherm for Prostate Cancer: Gelet (France), Vallencien (France)
• Laser Prostatectomy for BPH: – Peter Gilling (St Vincent's Hospital)
• Greenlight Laser Prostatectomy for BPH: Gordon Muir (London)
• Low Dose Rate Brachytherapy: – Michael Zelevsky (St Vincent's Hospital), Keith Kaye (Western Australia)
• Advance Sling: – Paris June 2008
• Robotic Radical Prostatectomy: Vip Patel (St Vincent's Hospital), Ohio State University Medical Center (Florida Hospital)
• Focal Therapy: – Prof. Mark Emberton (UCLH London)

Membership

• Urological Society of Australasia
• American Urological Association
• European Urological Society
• Prostate Cancer Foundation of Australia
• Society International d'Urologie
• Royal Australian College of Surgeons
• Australian Prostate Cancer Collaboration
• NSW Urology Oncology Group
• Multidisciplinary cancer care team (MDT)

Positions Previously Held

1992–2013 Head, Prostate Cancer Group, Garvan Institute of Medical Research/St Vincent’s Hospital Campus

1998–2012 Inaugural Director of the Prostate Cancer Foundation of Australia

Recent Grants Held

2010–2014 NHMRC Enabling Grant (ID No. 614296). "Australian Prostate Cancer Collaboration (APCC) Bio–Resource”. Clements J, Sutherland RL, Tilley W, Risbridger G, Marshall V, Roder D, Stahl J, Gardiner F, Nicol D, Frydenberg M, Pedersen J, Stricker P. $2,000,000.00

2010–2015 Cancer Institute NSW Program Grant for Excellence in Translational Research. Personalised medicine for cancer: molecular biomarkers in clinical decision making for breast, prostate and pancreatic cancer. CIs: Horvath LG, Kench J, Boyer M, Millar E, O’Toole S, Beith J, Grimison P. AI: Stricker P. $3,750,000.00

2012–2013 St Vincent’s Clinic Foundation “K & A Collins” Grant. MRI Study. Stricker P. $50,000.00

2013–2017 Federal Government Grant – “The Chronic Disease Prevention and Service Improvement”. Australian Prostate Cancer Research Centre NSW. Mattick J, Spigelman A, Stricker P, Hayes V, Horvath L. $5,500,000.00

2016–2017 NHMRC Project Grant – “Epigenetic Changes in the Prostate Cancer Environment”. Clark S, Horvath L, Kench J, Stricker P et al. $848,954.00

2016–2017 Paul Ramsay Foundation – “Magnifi Trial”. Van Leeuwen P and Stricker P. $759,000.00

2016–2017 Paul Ramsay Foundation – “LuPSMA Trial”. Emmett L and Stricker P. $400,000.00

2017–2018 The John and Denise Cobcroft Cancer Research Grant/St Vincent’s Clinic Grant– “DETECT trial: Radioguided surgery with technetium99m–labelled PSMA to aid intra–operative lymph node metastases detection for patients undergoing robot–assisted radical prostatectomy and extended–pelvic lymph node dissection for prostate cancer”. Stricker P and Co–investigators. $30,000.00

2017–2018 Commonwealth Department of Health: Cancer Control – Australian Prostate Cancer Research Centres. Stricker P, Hayes V, Horvath L, Clarke S, Kench J, Joshua A, Rasiah K, Nguyen Q. $1,500,000.00

2019 – Commonwealth Department of Health: Australian Prostate Cancer Research Centre. Stricker P, Hayes V, Horvath L, Clarke S, Joshua A, Emmet L – $437,000.00

2019 – 2020 St. Vincent’s Clinic Foundation Grant. PRIMARY Trial – Can combined multiparametric MRI and PSMA PET imaging replace prostate biopsy in the primary diagnosis of prostate cancer? Emmett L and Stricker P. $40,000.00

2019 – 2020 St Vincent’s Curran Foundation Grant. PRIMARY Trial – A prospective evaluation of prostate–specific membrane antigen positron emission tomography (PSMA PET) to reduce unnecessary prostate biopsies in men at risk of prostate cancer.

Emmett L and Stricker P. $100,000.00

2019 – 2021 The Sydney Partnership for Health, Education, Research & Enterprise (SPHERE) – Additional diagnostic value of PSMA to mpMRI in the diagnostic setting: Ability to reduce unnecessary prostate biopsies in men being investigated for prostate cancer. PRIMARY Trial. Emmet L and Stricker P. $150,000.00

2019–2023 Cancer Institute of NSW Programme Grant. $4,000,000

Professional Experience

Open Radical Prostatectomy:

• Performed > 6500 cases
• Specialist in nerve sparing technique
• Mentored and trained Registrars, Fellows and Urological colleagues in nerve sparing technique
• Achieved international standard outcomes with <10% positive margins, up to 92% potency recovery and <2% long–term incontinence. These results have been presented and published in state, national and international meetings and journals

Robotic Radical Prostatectomy:

• Commenced first robotic program (Da Vinci Si) in NSW at St Vincent's Private Hospital in February 2006 and currently has one of the largest series in Australia
• Performed > 2,000 cases.
• First robotic surgeon to perform 2,000 robotic prostatectomies in NSW and third in Australia to achieve this milestone.
• Fully trained robotic Surgeon – particular expertise in nerve sparing robotic surgery
• Performed the first Dr Vip Patel nerve sparing technique radical prostatectomy in NSW
• Invited presenter at the World Robotic Symposium Ohio 2007 and Orlando 2008 & 2010, Weill Cornell Medical College New York 2011, FOI Urology ConferenceIsrael 2012 & 2016, Urology Society of Australia and New Zealand ASM2010 & 2014, Annual Urology Scientific meeting 2009 & 2010, APCC – Robotic Masterclass 2011, Asia Pacific PCC – Robotic Masterclass 2013, Sydney Robotic Symposium – Preservation of potency in Robotic RP 2017
• Excellent results with low positive margin rate (< 1% pT2), high continence (98%) and good potency results (>70% overall)
• Accredited mentor to other surgical units (Asia Pacific, Western Australia, Queensland & New Zealand)
• Associate Editor of Journal of Robotic Surgery
• Published personal series in The Journal “European Urology” 2014 & 2017, in addition to many other highly cited publications relating to robotic surgery
• Manages the Robotic Fellowship Program at St Vincent's Private Hospital
• Invited presenter at World Robotic Symposium (2020) hosted by Royal Prince Alfred Hospital and organised by the US–Based Society of Robotic surgery (SRS), to provide masterclasses with other urologists.

Low Dose Rate Brachytherapy (Seeds):

• Personal series of > 1000 cases since 1997. One of the largest series in Australasia
• Introduced Seeds to Eastern Australia in 1996
• Results have been presented and published at national and international meetings
• Mentored and trained many of the units in Australia
• In 2001, with the support of the Urological Society of Australia arranged the acceptance of Brachytherapy as an approved item number by Medicare in the therapy for prostate cancer

High Dose Rate Brachytherapy:

• Largest personal series in Australia and one of the largest series in the world, with >1000 cases performed personally since 1998
• Presented and published at national and international meetings
• Mentored and trained multiple Urologists in the technique
• Began the first program in Australia in 1998 with Mark Stevens

Focal Therapy (HIFU & Nanoknife IRE) for localized Prostate Cancer

• Commenced HIFU in October 2005 – the first unit in Australia
• Commenced Nanoknife (IRE) in 2013 as a focal therapy
• Currently conducting quarterly workshops to train academic centres throughout Australia, New Zealand, Europe and Asia in the technique of focal NanoKnife ablation for selected patients with prostate cancer. A central registry containing all results nationally and internationally will be maintained to help evaluate and improve the utility of this technique.
• One of four international academic sites evaluating Nanoknife (IRE) focal therapy
• Performed >300 cases of Focal IRE since 2013
• Published data on the largest prospective focal Nanoknife therapy cohort in the world in European Oncology Urology. This series contained 123 patients with a minimum follow–up period of 12 months, including MRI and biopsy follow–up. These patients showed 97% clearance of cancer infield and a 10% to 12% chance of recurrence in the outfield. These are interim results as part of a cohort containing 300 cases performed by Professor Stricker.

Active Surveillance:

• >1000 cases on active surveillance since 1999.
• The largest series in Australia.
• Structured program of follow–up with PSA, transperineal biopsies of the prostate and MRI scans.
• Chief Investigator in evaluation of mpMRI in monitoring active surveillance

Sexual Health Rehabilitation:

• Enormous experience in sexual rehabilitation and preservation and one of the acknowledged experts in Australia
• Set up one of the largest multidisciplinary sexual dysfunction clinics in the Southern Hemisphere (the Australian Centre for Sexual Health 1991–2001)
• Trained Dr Michael Lowy who now has particular expertise in this area
• Investigator in the original research on Viagra on the protection of potency after radical prostatectomy surgery, being one of the highest accrual centers in the world and the largest in Australia.
• Currently still involved in multiple projects pertaining to sexual rehabilitation after surgery

Incontinence Therapy after Prostate Cancer Treatment:

• Personal series of >150 cases of insertion of artificial urinary sphincter for severe urinary incontinence. His experience includes the more complex artificial sphincter cases such as the use of double cuffs, complex revisions, transcorporal implantation and complex erosions. He was trained by Professor Richard Millard and Professor Robert Farnsworth.
• Post radical prostatectomy incontinence – Professor Stricker has been treating post radical prostatectomy incontinence for 30 years. He has developed a tertiary referral practice from many urologists including Dr Carlo Yuen, Dr Phillip Brenner, Dr Haxhimolla, Dr Jefferson and previously David Golovsky. Trained by Prof Millard, S Raz, Rodney Appell, Ed Mcguire and Dean Knoll.
• Large experience in the use of the ProAct Device (50–100 cases) and Collagen Implant in the treatment of minor urinary incontinence.
• Works in close association with a dedicated pelvic floor Physiotherapist Stuart Baptist in managing incontinence and post RP recovery.
• Urodynamics – Professor Stricker has personally performed a large volume of urodynamic procedures since 1988 for approximately 15 years. He was taught by Professor Richard Millard. The technique he used was video urodynamic assessment. When his practice became too busy to perform the urodynamic assessments, he continued to assess incontinent patients and referred the patients for urodynamic assessment to Professor Millard and after his retirement to Vincent Tse and then Lewis Chan.
• Sling procedures – Extensive and long experience in InVance and AdVance slings including the more recent AdVance XP sling, having performed these regularly for almost 20 years. He was trained by the initiator of the transobturator sling Dr Dean Knoll and further formal training in Paris in 2008. In addition, he has been a teacher to many urologists and trainees in sling surgery including Dr David Jefferson, Richard Savdie, Carlo Yuen, Kris Rasiah, Anthony Hutton, Phil Brenner and Peter Chin as well as his fellows and registrars.

Second Opinion Service:

• Over 20 years of experience in tailoring and personalising treatment to patient's needs
• Initiated a large multidisciplinary team for appropriate support throughout all treatments
• Offers second opinion website advice – https://www.phillipstricker.com.au/my–practice/second–opinion

Transperineal Grid–directed Prostate Biopsy Technique:

• Developed and first described this technique internationally in 1997
• Over 7000 cases performed
• Has minimised the chance of post biopsy sepsis using this technique
• Has presented and published on this technique nationally and internationally
• Has mentored and trained Urologists, Fellows and Registrars in this technique
• Invited chapter in Hinman’s Atlas of Urology 4th Edition

Magnetic Resonance Imaging and Spectroscopy (MRI/MRS):

• This technique has the potential in improving the accuracy of diagnosis, minimizing invasive procedures and in monitoring patients
• First looked at the accuracy of this technology in prostate in 2007. In 2012 initiated several studies at St Vincent’s Campus evaluating MRI accuracy in comparison to prostate biopsies, PCA3 and prostate health index (PHI). Initial results from the study were presented at the AUA in San Diego in May 2013
• International and national teacher of the role of MRI in prostate cancer

PSMA PET Screening

• Initiated the first unit in New South Wales
• Published multiple prospective studies on the accuracy of this technology
• International & national speaker on PSMA

Clinical Trials

• Extensive experience in designing and conducting clinical trials examining the proliferation and treatment of prostate cancer and improve the accuracy of treatment of prostate cancer, particularly with the use of high–quality MRI and PET scanning.
• The results of Professor Stricker’s clinical trials have been published in numerous high impact journals and are widely cited nationally and internationally.
• Collaboration with many national and International registries and agencies to collate outcomes data on prostate cancer.
• Professor Stricker is the Chief Investigator and Principal Investigator of numerous clinical trials:
• The DETECT Trial – This is using aGeiger counter to detect early cancer spread during the operation to more accurately remove lymph glands which may be affected by cancer more accurately.
• The PRIMARY Trial – This trial is a multi–centre project looking at the use of PSMA PET scanning in the evaluation of patients under suspicion for prostate cancer. This trial is aiming to see if PSMA PET Scanning can improve Prostate Cancer Detection in addition to MRI Scanning, ultimately resulting in a reduction in the need to perform unnecessary biopsies. Professor Stricker isthe principal investigator with Louise Emmett
• New PSMA PET Scan Agent – This is a trial evaluating a new type of PSMA PET to improve accuracy of prostate cancer detection. Professor Stricker isthe principal investigator with Louise Emmett
• The MRIAS Study – An observational cohort study of multi–parametric MRI in active surveillance for low risk prostate cancer. Professor Stricker is the Chief Investigator
• FIRE study – A prospective interventional pilot study of patients who underwent irreversible electroporation (IRE) as salvage treatment for radio–recurrent prostate cancer to assess the safety profile of IRE, as well as functional and oncological outcomes based on multi–parametric magnetic resonance imaging (mpMRI) and transperineal template mapping biopsy (TTMB) at 1year post treatment. Professor Stricker is the Chief Investigator
• ROTI study – The use of pre–treatment prostate specific membrane antigen (PSMA) PET and Magnetic Resonance Imaging (MRI) for men with high–risk disease and pelvic lymph nodes so as to increase the therapeutic outcome at three years with minimal genitourinary (GU) and gastrointestinal (GI) toxicity. Professor Stricker isthe principal investigator with Louise Emmett
• Quality of life (QoL) study – Assess how each treatment modality currently being offered for localized prostate cancer at St. Vincent’s Private Hospital affects the patients QOL, and how this may impact on the patient’s preference for a particular treatment.

Recent Awards

• Awarded Australia’s 2 ^nd highest award , Officer of the Order of Australia (AO) on the Australia Day 2015 Honours list for “ Distinguished service to medicine and medical research , as a leading urologist , a robotic surgery pioneer , a teacher and mentor , and as an advocate for prostate cancer awareness.”
• Top 10% downloaded publication in BJUI International for:
  • Gallium‐68‐prostate‐specific membrane antigen (68Ga‐PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate‐ and high‐risk prostate cancer
  • Use of gallium‐68 prostate‐specific membrane antigen positron‐emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literatu re
• Top 10% downloaded publication in Journal of Magnetic Resonance Imaging for:
  • Radiomic features on MRI enable risk categorization of prostate cancer patients on active surveillance: Preliminary findings
• British Journal of Urology International Global prize 2018 – Best paper published between 1 July 2016 and 30 June 2017
  • This award was received for the publication “Prospective evaluation of 68gallium–prostate–specific–membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer”.
• British Journal of Urology International Global Prize 2019 – Best paper published between 1 July 2017 and 30 June 2018
  • This award was received for the publication “Initial multicenter experience of 68gallium–PSMA PETCT guided robot–assisted salvage lymphadenectomy: acceptable safety profile by oncological benefit appears limited”.
  • The award was presented to Urology Fellow, Dr. Amila Siriwardana, at USANZ Brisbane 2019, and is reflective of the contributions being made to PSMA PET/CT research by Professor Stricker’s research team.
• European Association of Urology Best Poster – 34 ^th Annual EAU Congress, 15–19 March 2019, Barcelona, Spain
  • This award was received by Urology Fellow Dr. Alexandar Blazevski on behalf of Professor Stricker for the poster “Salvage irreversible electroporation for locally recurrent prostate cancer after radiotherapy – oncologic and functional outcomes”
• Urology fellow Dr. Alexandar Blazevski was awarded a High Distinction for his Master of Surgery (Urology) Thesis titled “Oncological outcomes of focal irreversible electroporation (IRE) for clinically significant prostate cancer.
  • Professor Stricker was the Principal Supervisor for this thesis and will continue to be the Principal Supervisor for Dr. Blazevski’s Doctor of Philosophy (Phd) Urology commencing in 2019.
• Professor Stricker was the first robotic surgeon in New South Wales and the third in Australia to successfully complete 2,000 robotic radical prostatectomies. He has paid tribute to the outstanding team of nurses, assistants and anesthetists at St Vincent’s, emphasizing how critical they have been to the success of the program at this hospital.

Publications

1. Stricker, P. D., A. B. F. Grant, B. M. Hosken, and J. S. Taylor. 1987. 'Topical Mitomycin C Therapy for Carcinoma of the Bladder', The Journal of Urology, 138: 1164–66.
   
   https://doi.org/10.1016/S0022–5347(17)43537–3
2. Stricker, P.D., and A. B. F. Grant. 1988. 'Relative Value of Antibiotics and Catheter Care in the Prevention of Urinary Tract Infection after Transurethral Prostatic Resection', British Journal of Urology, 61: 494–97.
   https://doi.org/10.1111/j.1464–410X.1988.tb05087.x
3. Stricker, P. D., A. B. F. Grant, B. M. Hosken, and J. S. Taylor. 1990. 'Topical Mitomycin C Therapy for Carcinoma in Situ of the Bladder: A Followup', The Journal of Urology, 143: 34–35.
   https://doi.org/10.1016/S0022–5347(17)39855–5
4. Stricker, P. D. 1991. 'The Investigation of Male Sexual Dysfunction (Review)', Medical Journal of Australia.
5. Pryor, K., J. Goddard, D. Goldstein, P. Stricker, P. Russell, D. Golovsky, and R. Penny. 1995. 'Bacillus Calmette–Guerin (BCG) enhances monocyte– and lymphocyte–mediated bladder tumour cell killing', Br J Cancer, 71: 801–7.
6. Pryor, K., P. Stricker, P. Russell, D. Golovsky, and R. Penny. 1995. 'Antiproliferative effects of bacillus Calmette–Guerin and interferon alpha 2b on human bladder cancer cells in vitro', Cancer Immunol Immunother, 41: 309–16.
7. Stricker, P. 1995. 'Advances in the treatment of superficial bladder cancer: Optimising BCG Immunotherapy Case Discussions', European Urology: Supp, 32–33.
8. Millard, R. J., P. D. Stricker, and W. Lynch. 1996. 'Risks of self–injection therapy for impotence', The Medical Journal of Australia, 165: 117–18.
9. Stricker, P. 1996. 'Prostate Cancer: Don't be too casual', The Medical Journal of Australia, 164: 319–20.
10. Stricker, P., K. Pryor, T. Nicholson, D. Goldstein, D. Golovsky, R. Ferguson, P. Nash, S. Ehsman, J. Rumma, G. Mammen, and R. Penny. 1996. 'Bacillus Calmette–Guerin plus intravesical interferon alpha–2b in patients with superficial bladder cancer', Urology, 48: 957–61; discussion 61–2.
11. Frydenberg, M., P. D. Stricker, and K. W. Kaye. 1997. 'Prostate cancer diagnosis and management', The Lancet, 349: 1681–87.
    https://doi.org/10.1016/S0140–6736(96)07393–X
12. Frydenberg, M, G. Duchesne, and P. D. Stricker. 1998. 'Management of localised prostate cancer: state of the art', Med J Aust,169: 11– 2.
13. Russell, P. J., S. Bennett, and P. Stricker. 1998. 'Growth factor involvement in progression of prostate cancer', Clin Chem, 44: 705–23.
14. Ricciardelli, C., D. I. Quinn, W. A. Raymond, K. McCaul, P. D. Sutherland, P. D. Stricker, J. J. Grygiel, R. L. Sutherland, V. R. Marshall, W. D. Tilley, and D. J. Horsfall. 1999. 'Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early–stage prostate cancer', Cancer Res, 59: 2324–8.
15. Kooner, R, and P. Stricker. 2000. 'Lower urinary tract symptoms in the male. Benign prostatic hyperplasia', MedicineToday: 20–33.
16. Quinn, D. I., S. M. Henshall, D. R. Head, D. Golovsky, J. D. Wilson, P. C. Brenner, J. J. Turner, W. Delprado, J. F. Finlayson, P. D. Stricker, J. J. Grygiel, and R. L. Sutherland. 2000. 'Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy', Cancer Res, 60: 1585–94.
17. Henshall, S. M., D. I. Quinn, C. S. Lee, D. R. Head, D. Golovsky, P. C. Brenner, W. Delprado, P. D. Stricker, J. J. Grygiel, and R. L. Sutherland. 2001. 'Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer', Cancer Res, 61: 423–7.
18. Henshall, S. M., D. I. Quinn, C. S. Lee, D. R. Head, D. Golovsky, P. C. Brenner, W. Delprado, P. D. Stricker, J. J. Grygiel, and R. L. Sutherland. 2001. 'Overexpression of the cell cycle inhibitor p16INK4A in high–grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients', Clin Cancer Res, 7: 544–50.
19. Horvath, L. G., S. M. Henshall, C. S. Lee, D. R. Head, D. I. Quinn, S. Makela, W. Delprado, D. Golovsky, P. C. Brenner, G. O'Neill, R. Kooner, P. D. Stricker, J. J. Grygiel, J. A. Gustafsson, and R. L. Sutherland. 2001. 'Frequent loss of estrogen receptor–beta expression in prostate cancer', Cancer Res, 61: 5331–5.
20. Quinn, D. I., S.M. Henshall, A.M. Haynes, P. C. Brenner, R. Kooner, D. Golovsky, J. Mathews, G. F. O’Neill, J. J. Turner, W. Delprado, J. F. Finlayson, R. L. Sutherland, J. J. Grygiel, and P. D. Stricker. 2001. 'Prognostic Significance of Pathologic Features in Localized Prostate Cancer Treated With Radical Prostatectomy: Implications for Staging Systems and Predictive Models', Journal of Clinical Oncology, 19: 3692–705.
    https://doi.org/10.1200/jco.2001.19.16.3692
21. Stricker, P. 2001. 'Prostate Cancer Part 1. Issues in Screening and Diagnosis', MedicineToday: 20–31.
22. Stricker, P. 2001. 'Prostate Cancer Part 2. – Options in Treatment', MedicineToday, 2: 30–38.
23. Graefen, M., P. I. Karakiewicz, I. Cagiannos, E. Klein, P. A. Kupelian, D. I. Quinn, S. M. Henshall, J. J. Grygiel, R. L. Sutherland, P. D. Stricker, J. de Kernion, T. Cangiano, F. H. Schroder, M. F. Wildhagen, P. T. Scardino, and M. W. Kattan. 2002. 'Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer', J Clin Oncol, 20: 951–6.
    https://doi.org/10.1200/jco.2002.20.4.951
24. Graefen, M., P. I. Karakiewicz, I. Cagiannos, D. I. Quinn, S. M. Henshall, J. J. Grygiel, R. L. Sutherland, P. D. Stricker, E. Klein, P. Kupelian, D. G. Skinner, G. Lieskovsky, B. Bochner, H. Huland, P. G. Hammerer, A. Haese, A. Erbersdobler, J. A. Eastham, J. de Kernion, T. Cangiano, F. H. Schroder, M. F. Wildhagen, T. H. van der Kwast, P. T. Scardino, and M. W. Kattan. 2002. 'International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy', J Clin Oncol, 20: 3206–12.
    https://doi.org/10.1200/jco.2002.12.019
25. Cagiannos, I., P. Karakiewicz, J. A. Eastham, M. Ohori, F. Rabbani, C. Gerigk, V. Reuter, M. Graefen, P. G. Hammerer, A. Erbersdobler, H. Huland, P. Kupelian, E. Klein, D. I. Quinn, S. M. Henshall, J. J. Grygiel, R. L. Sutherland, P. D. Stricker, C. G. Morash, P. T. Scardino, and M. W. Kattan. 2003. 'A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer', J Urol, 170:1798–803.
    https://doi.org/10.1097/01.ju.0000091805.98960.13
26. Henshall, S. M., D. E. Afar, J. Hiller, L. G. Horvath, D. I. Quinn, K. K. Rasiah, K. Gish, D. Willhite, J. G. Kench, M. Gardiner–Garden, P. D. Stricker, H. I. Scher, J. J. Grygiel, D. B. Agus, D. H. Mack, and R. L. Sutherland. 2003. 'Survival analysis of genome–wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse', Cancer Res, 63: 4196–203.
27. Henshall, S. M., D. E. Afar, K. K. Rasiah, L. G. Horvath, K. Gish, I. Caras, V. Ramakrishnan, M. Wong, U. Jeffry, J. G. Kench, D. I. Quinn, J. J. Turner, W. Delprado, C. S. Lee, D. Golovsky, P. C. Brenner, G. F. O'Neill, R. Kooner, P. D. Stricker, J. J. Grygiel, D. H. Mack, and R. L. Sutherland. 2003. 'Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer', Oncogene, 22: 6005–12.
    https://doi.org/10.1038/sj.onc.1206797
28. MJ, Stevens, Stricker PD, Saalfeld J, Brenner PC, Kooner R, O'Neill GFA, Duval PJ, Jagavkar RS, Cross P, and Martland J. 2003. 'Treatment of localized prostate cancer using a combination of high dose rate Iridium‐192 brachytherapy and external beam irradiation: Initial Australian experience', Australasian Radiology, 47: 152–60.
    https://doi.org/10.1046/j.0004–8461.2003.01143.x
29. Quinn, D. I., S. M. Henshall, P. C. Brenner, R. Kooner, D. Golovsky, G. F. O'Neill, J. J. Turner, W. Delprado, J. J. Grygiel, R. L. Sutherland, and P. D. Stricker. 2003. 'Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion', Cancer, 97: 1884–93.
    https://doi.org/10.1002/cncr.11263
30. Rasiah, K. K., P. D. Stricker, A. M. Haynes, W. Delprado, J. J. Turner, D. Golovsky, P. C. Brenner, R. Kooner, G. F. O'Neill, J. J. Grygiel, R. L. Sutherland, and S. M. Henshall. 2003. 'Prognostic significance of Gleason pattern in patients with Gleason score 7 prostate carcinoma', Cancer, 98: 2560–5.
    https://doi.org/10.1002/cncr.11850
31. Adshead, J, and P. Stricker. 2004. 'Localised Prostate Cancer – Questions Patients Ask', MedicineToday, 5: 18–32.
32. Afar, D. E., V. Bhaskar, E. Ibsen, D. Breinberg, S. M. Henshall, J. G. Kench, M. Drobnjak, R. Powers, M. Wong, F. Evangelista, C. O'Hara, D. Powers, R. B. DuBridge, I. Caras, R. Winter, T. Anderson, N. Solvason, P. D. Stricker, C. Cordon–Cardo, H. I. Scher, J. J. Grygiel, R. L. Sutherland, R. Murray, V. Ramakrishnan, and D. A. Law. 2004. 'Preclinical validation of anti–TMEFF2–auristatin E– conjugated antibodies in the treatment of prostate cancer', Mol Cancer Ther, 3: 921–32.
33. Cagiannos, I., P. Karakiewicz, M. Graefen, J. A. Eastham, M. Ohori, F. Rabbani, V. Reuter, T. Wheeler, P. Kupelian, E. Klein, H. Huland, P. G. Hammerer, A. Erbersdobler, F. Schroeder, M. Wildhagen, D. I. Quinn, S. M. Henshall, J. J. Grygiel, R. L. Sutherland, P. D. Stricker, C. G. Morash, P. T. Scardino, and M. W. Kattan. 2004. 'Is year of radical prostatectomy a predictor of outcome in prostate cancer?', J Urol, 171: 692–6.
    https://doi.org/10.1097/01.ju.0000107260.98031.0e
34. Haxhimolla, H, S.P. David, K. K. Rasiah, A. M. Haynes, K Luo, D. Golovsky, and P. Stricker. 2004. 'Solitary positive apical margin a treatment dilema', ANZ Journal of Surgery, 74: A1–A8.
35. Hoch, M, K. K. Rasiah, H Haxhimolla, A. M. Haynes, and P. Stricker. 2004. 'Determining predictors of insignificant cancer in Gleason sum 6 prostate cancer', ANZ Journal of Surgery, 74.
36. Horvath, L. G., S. M. Henshall, J. G. Kench, D. N. Saunders, C. S. Lee, D. Golovsky, P. C. Brenner, G. F. O'Neill, R. Kooner, P. D. Stricker, J. J. Grygiel, and R. L. Sutherland. 2004. 'Membranous expression of secreted frizzled–related protein 4 predicts for good prognosis in localized prostate cancer and inhibits PC3 cellular proliferation in vitro', Clin Cancer Res, 10: 615–25.
37. Horvath, L. G., S. M. Henshall, J. G. Kench, J. J. Turner, D. Golovsky, P. C. Brenner, G. F. O'Neill, R. Kooner, P. D. Stricker, J. J. Grygiel, and R. L. Sutherland. 2004. 'Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression', Prostate, 59: 234–42.
    https://doi.org/10.1002/pros.10361
38. Montorsi, F., P. Stricker, E. Jaudinot, C. Wohlhuter, P. Puppo, and P. Teillac. 2004. 'Stratification by outcomes affecting response to Viagra in the treatment of erectile dysfunction during the first 6 months following radical prostatectomy', European Urology Supplements, 3: 32.
    https://doi.org/10.1016/S1569–9056(04)90121–2
39. Rasiah, K. K., S. M. Henshall, J. G. Kench, L. G. Horvath, D. Golovsky, P. C. Brenner, R Kooner, G. O'Neill, J. J. Turner, W. Delprado, C. S. Lee, and P.D. Stricker. 2004. 'Identification of novel markers of prognosis in high grade intraepithelial neoplasia and early prostate cancer', ANZ Journal of Surgery, 74: A1–A8.
40. Stricker, P., J Matthews, and A. M. Haynes. 2004. 'Radical Prostatectomy: A personal series of 700 cases over 14 years: Evolution in technique', ANZ Journal of Surgery, 74: A1–A8.
41. Teillac, P., P. Stricker, E. Jaudinot, C. Wohlhuter, and F. Montorsi. 2004. 'Efficacy and safety of Viagra in the treatment of erectile dysfunction during the first 6 months following radical prostatectomy', European Urology Supplements, 3: 33.
    https://doi.org/10.1016/S1569–9056(04)90124–8
42. Bauskin, A. R., D. A. Brown, S. Junankar, K. K. Rasiah, S. Eggleton, M. Hunter, T. Liu, D. Smith, T. Kuffner, G. J. Pankhurst, H. Johnen, P. J. Russell, W. Barret, P. D. Stricker, J. J. Grygiel, J. G. Kench, S. M. Henshall, R. L. Sutherland, and S. N. Breit. 2005. 'The propeptide mediates formation of stromal stores of PROMIC–1: role in determining prostate cancer outcome', Cancer Res, 65: 2330–6.
    https://doi.org/10.1158/0008–5472.can–04–3827
43. Finney, G., A. M. Haynes, P. Cross, P. Brenner, A. Boyn, and P. Stricker. 2005. 'Cross–sectional analysis of sexual function after prostate brachytherapy', Urology, 66: 377–81.
    https://doi.org/10.1016/j.urology.2005.03.045
44. Horvath, L. G., S. M. Henshall, C. S. Lee, J. G. Kench, D. Golovsky, P. C. Brenner, G. F. O'Neill, R. Kooner, P. D. Stricker, J. J. Grygiel, and R. L. Sutherland. 2005. 'Lower levels of nuclear beta–catenin predict for a poorer prognosis in localized prostate cancer', Int J Cancer, 113: 415–22.
    https://doi.org/10.1002/ijc.20599
45. Karakiewicz, P. I., J. A. Eastham, M. Graefen, I. Cagiannos, P. D. Stricker, E. Klein, T. Cangiano, F. H. Schroder, P. T. Scardino, and M. W. Kattan. 2005. 'Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi–institutional assessment of 5831 patients', Urology, 66: 1245–50.
    https://doi.org/10.1016/j.urology.2005.06.108
46. Macek, P, D Patel, and P. Stricker. 2005. 'Assessing and managing benign prostatic hyperplasia', MedicineToday, 6: 12–22.
47. Henshall, S. M., L. G. Horvath, D. I. Quinn, S. A. Eggleton, J. J. Grygiel, P. D. Stricker, A. V. Biankin, J. G. Kench, and R. L. Sutherland. 2006. 'Zinc–alpha2–glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy', J Natl Cancer Inst, 98: 1420–4.
    https://doi.org/10.1093/jnci/djj378
48. Macek, P, P. Stricker, M. Stevens, R. Jagavkar, V. Chalasani, A.M. Haynes, J Mathews, P. Brenner, D. Golovsky, R Kooner, and F. O'Neill G. 2006. 'Outcomes of radical prostatectomies and HDR brachytherapy in patients with intermediate and high risk prostate cancer', BJU International, 97: 3–3.
    https://doi.org/10.1111/j.1464–410X.2006.06085_12.x
49. Rasiah, K. K., J. G. Kench, M. Gardiner–Garden, A. V. Biankin, D. Golovsky, P. C. Brenner, R. Kooner, F. O'Neill G, J. J. Turner, W. Delprado, C. S. Lee, D. A. Brown, S. N. Breit, J. J. Grygiel, L. G. Horvath, P. D. Stricker, R. L. Sutherland, and S. M. Henshall. 2006. 'Aberrant neuropeptide Y and macrophage inhibitory cytokine–1 expression are early events in prostate cancer development and are associated with poor prognosis', Cancer Epidemiol Biomarkers Prev, 15: 711–6.
    https://doi.org/10.1158/1055–9965.epi–05–0752
50. Stevens, M., P.D. Stricker, J. Saalfeld, P. Brenner, and R Kooner. 2006. 'Treatment of localised prostate cancer using a combination of high dose‐rate Ir‐192 brachytherapy (HDRB) and external beam radiation therapy (EBRT): a 7 year experience', BJU International, 97: 3–4.
    https://doi.org/10.1111/j.1464–410X.2006.06085_13.x
51. Chabert, C., Z. Maianski, and P. Stricker. 2007. 'Saw palmetto and lower urinary tract symptoms in men', MedicineToday, 8: 71–72.
52. Ho, L. L., J. G. Kench, D. J. Handelsman, G. L. Scheffer, P. D. Stricker, J. G. Grygiel, R. L. Sutherland, S. M. Henshall, J. D. Allen, and L. G. Horvath. 2008. 'Androgen regulation of multidrug resistance– associated protein 4 (MRP4/ABCC4) in prostate cancer', Prostate, 68: 1421–9.
    https://doi.org/10.1002/pros.20809
53. Padma–Nathan, H., A. R. McCullough, L. A. Levine, L. I. Lipshultz, R. Siegel, F. Montorsi, F. Giuliano, and G. Brock. 2008. 'Randomized, double–blind, placebo–controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve–sparing radical prostatectomy', Int J Impot Res, 20: 479–86.
    https://doi.org/10.1038/ijir.2008.33
54. Sakko, A. J., M. S. Butler, S. Byers, B. J. Reinboth, J. Stahl, J. G. Kench, L. G. Horvath, R. L. Sutherland, P. D. Stricker, S. M. Henshall, V. R. Marshall, W. D. Tilley, D. J. Horsfall, and C. Ricciardelli. 2008. 'Immunohistochemical level of unsulfated chondroitin disaccharides in the cancer stroma is an independent predictor of prostate cancer relapse', Cancer Epidemiol Biomarkers Prev, 17: 2488–97.
    https://doi.org/10.1158/1055–9965.epi–08–0204
55. Stricker, P. 2008. 'Approaches to Nerve Sparing Retrograde Athermal Technique', Journal of Robotic Surgery, 2: 105–33.
56. Stricker, P. 2008. 'Ethical Introduction to Robotic Radical Prostatectomy Surgery for an Experienced Open Surgeon', Journal of Robotic Surgery, 2: 105–33.
57. Chabert, C., and P. Stricker. 2009. 'Treatment for Localised Prostate Cancer', MedicineToday, 10: 63–66.
58. Chen, P., R. Thanigasalam, P. Stricker, J Mathews, R. DeBenito, A. M. Haynes, S. M. Henshall, and K. K. Rasiah. 2009. 'The Clinico– Pathological Outcome of Men Undergoing Prostatectomy with PSA < 4 ', BJUI International, 103: 1–48.
    https://doi.org/10.1111/j.1464–410X.2009.09021.x
59. Chen, P., R. Thanigasalm, S. M. Henshall, A. M. Haynes, J Mathews, and P. Stricker. 2009. 'Prospective Comparative Analysis of Clinico–Pathological Outcomes Between Robotic Assisted and Open Radical Prostatectomy', BJUI International, 103: 1–48.
    https://doi.org/10.1111/j.1464–410X.2009.09021.x
60. Rasiah, K. K., M. Gardiner–Garden, E. J. Padilla, G. Moller, J. G. Kench, M. C. Alles, S. A. Eggleton, P. D. Stricker, J. Adamski, R. L. Sutherland, S. M. Henshall, and V. M. Hayes. 2009. 'HSD17B4 overexpression, an independent biomarker of poor patient outcome in prostate cancer', Mol Cell Endocrinol, 301: 89–96.
    https://doi.org/10.1016/j.mce.2008.11.021
61. Smith, David P, Madeleine T King, Sam Egger, Martin P Berry, Phillip D Stricker, Paul Cozzi, Jeanette Ward, Dianne L O’Connell, and Bruce K Armstrong. 2009. 'Quality of life three years after diagnosis of localised prostate cancer: population based cohort study', BMJ, 339.
    https://doi.org/10.1136/bmj.b4817
62. Stricker, P. 2009. 'A Practical Guide on PSA Testing', MedicineToday, 10.
63. Bianco–Miotto, T., K. Chiam, G. Buchanan, S. Jindal, T. K. Day, M. Thomas, M. A. Pickering, M. A. O'Loughlin, N. K. Ryan, W. A. Raymond, L. G. Horvath, J. G. Kench, P. D. Stricker, V. R. Marshall, R. L. Sutherland, S. M. Henshall, W. L. Gerald, H. I. Scher, G. P. Risbridger, J. A. Clements, L. M. Butler, W. D. Tilley, D. J. Horsfall, and C. Ricciardelli. 2010. 'Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development', Cancer Epidemiol Biomarkers Prev, 19: 2611–22.
    https://doi.org/10.1158/1055–9965.epi–10–0555
64. Doumerc, N., C. Yuen, R. Savdie, M. B. Rahman, R. Pe Benito, and P. Stricker. 2010. 'Robot–assisted laparoscopic prostatectomy: analysis of an experienced open surgeon's learning curve after 300 procedures', J Robot Surg, 3: 229–34.
    https://doi.org/10.1007/s11701–010–0171–5
65. Doumerc, N., C. Yuen, R. Savdie, M. B. Rahman, K. K. Rasiah, R. Pe Benito, W. Delprado, J. Matthews, A. M. Haynes, and P. D. Stricker. 2010. 'Should experienced open prostatic surgeons convert to robotic surgery? The real learning curve for one surgeon over 3 years', BJU Int, 106: 378–84.
    https://doi.org/10.1111/j.1464–410X.2009.09158.x
66. Moore, B., R. DeBenito, A. M. Haynes, and P. Stricker. 2010. 'The Impact of Nerve Sparing Surgical Margins Status and Oncological Outcome in Radical Prostatectomy', BJU International Authours Journal Compliation, 105: 1–38.
    https://doi.org/10.1111/j.1464–410X.2010.09122.x
67. Talantov, D., T. A. Jatkoe, M. Bohm, Y. Zhang, A. M. Ferguson, P. D. Stricker, M. W. Kattan, R. L. Sutherland, J. G. Kench, Y. Wang, and S. M. Henshall. 2010. 'Gene based prediction of clinically localized prostate cancer progression after radical prostatectomy', J Urol, 184: 1521–8.
    https://doi.org/10.1016/j.juro.2010.05.084
68. Thanigasalam, R., K. K. Rasiah, P. D. Stricker, A. M. Haynes, S. I. Sutherland, R. L. Sutherland, S. M. Henshall, and L. G. Horvath. 2010. 'Stage migration in localized prostate cancer has no effect on the post–radical prostatectomy Kattan nomogram', BJU Int, 105: 642–7.
    https://doi.org/10.1111/j.1464–410X.2009.08842.x
69. Yip, P. Y., J. G. Kench, K. K. Rasiah, R. P. Benito, C. S. Lee, P. D. Stricker, S. M. Henshall, R. L. Sutherland, and L. G. Horvath. 2011. 'Low AZGP1 expression predicts for recurrence in margin–positive, localized prostate cancer', Prostate, 71: 1638–45.
    https://doi.org/10.1002/pros.21381
70. Yuen, C., and P. Stricker. 2011. 'Advances in the management of benign prostatic hyperplasia', MedicineToday, 12.
71. Stricker P.D., Frydenberg M., Kneebone A., and Chopra S..2012. 'Informed prostate cancer risk‐adjusted testing: a new paradigm', BJU International, 110: 30–34.
    https://doi.org/10.1111/j.1464–410X.2012.11621.x
72. Hossack, T., M. I. Patel, A. Huo, P. Brenner, C. Yuen, D. Spernat, J. Mathews, A. M. Haynes, R. Sutherland, W. del Prado, and P. Stricker. 2012. 'Location and pathological characteristics of cancers in radical prostatectomy specimens identified by transperineal biopsy compared to transrectal biopsy', J Urol, 188: 781–5.
    https://doi.org/10.1016/j.juro.2012.05.006
73. Huo, A. S., T. Hossack, J. L. Symons, R. PeBenito, W. J. Delprado, P. Brenner, and P. D. Stricker. 2012. 'Accuracy of primary systematic template guided transperineal biopsy of the prostate for locating prostate cancer: a comparison with radical prostatectomy specimens', J Urol, 187: 2044–9.
    https://doi.org/10.1016/j.juro.2012.01.066
74. King, M. T., R. Viney, D. P. Smith, I. Hossain, D. Street, E. Savage, S. Fowler, M. P. Berry, M. Stockler, P. Cozzi, P. Stricker, J. Ward, and B. K. Armstrong. 2012. 'Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer', British Journal of Cancer, 106: 638–45.
    https://doi.org/10.1038/bjc.2011.552
75. Moore, B. M., R. Savdie, R. A. PeBenito, A. M. Haynes, J. Matthews, W. Delprado, K. K. Rasiah, and P. D. Stricker. 2012. 'The impact of nerve sparing on incidence and location of positive surgical margins in radical prostatectomy', BJU Int, 109: 533–8.
    https://doi.org/10.1111/j.1464–410X.2011.10361.x
76. Savdie, R., L. G. Horvath, R. P. Benito, K. K. Rasiah, A. M. Haynes, M. Chatfield, P. D. Stricker, J. J. Turner, W. Delprado, S. M. Henshall, R. L. Sutherland, and J. G. Kench. 2012. 'High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy', BJU Int, 109: 1794–800.
    https://doi.org/10.1111/j.1464–410X.2011.10572.x
77. Savdie, R., J. Symons, D. Spernat, C. Yuen, R. A. Pe Benito, A. M. Haynes, J. Matthews, K. K. Rasiah, R. S. Jagavkar, C. Yu, G. Fogarty, M. W. Kattan, P. Brenner, R. L. Sutherland, and P. D. Stricker. 2012. 'High–dose rate brachytherapy compared with open radical prostatectomy for the treatment of high–risk prostate cancer: 10 year biochemical freedom from relapse', BJU Int, 110 Suppl 4: 71–6.
    https://doi.org/10.1111/j.1464–410X.2012.11480.x
78. Smith, D., D O'Connell, A Bang, M. T. King, M. P. Berry, P. Stricker, P. Cozzi, and B. K. Armstrong. 2012. 'Survival in men diagnosed with prostate cancer: 8 to 10 year outcomes from the NSW Prostate Cancer Care and Outcomes Study', Abstract for Sydney Cancer Conference.
79. Yuen, C., T Hoassack, A. M. Haynes, R. DeBenito, J Mathews, G. Fogarty, R. S. Jagavkar, P. Brenner, and P. Stricker. 2012. 'Impact of percentage of positive biopsy cores on biochemical outcome in patients treated with low–dose rate (Iodine–125) brachytherapy for prostate cancer', The Open Prostate Cancer Journal, 5: 15–19.
80. Beattie, K., J. Symons, S. Chopra, C. Yuen, R. Savdie, R. Thanigasalam, A. M. Haynes, J. Matthews, P. C. Brenner, K. Rasiah, R. L. Sutherland, and P. D. Stricker. 2013. 'A novel method of bladder neck imbrication to improve early urinary continence following robotic–assisted radical prostatectomy', Journal of Robotic Surgery, 7: 193–99.
    https://doi.org/10.1007/s11701–012–0371–2
81. Selth, L. A., S. L. Townley, A. G. Bert, P. D. Stricker, P. D. Sutherland, L. G. Horvath, G. J. Goodall, L. M. Butler, and W. D. Tilley. 2013. 'Circulating microRNAs predict biochemical recurrence in prostate cancer patients', Br J Cancer, 109: 641–50.
    https://doi.org/10.1038/bjc.2013.369
82. Symons, J. L., A. Huo, C. L. Yuen, A. M. Haynes, J. Matthews, R. L. Sutherland, P. Brenner, and P. D. Stricker. 2013. 'Outcomes of transperineal template–guided prostate biopsy in 409 patients', BJU Int, 112: 585–93. https://doi.org/10.1111/j.1464–410X.2012.11657.x
83. Thanigasalam, R., H. Baumert, P. Stricker, P. Brenner, S. Egger, S. Chopra, J. Symons, R. Savdie, A. Haynes, M. Bohm, A. Elhajj, D. Smith, R. Sutherland, and K. Rasiah. 2013. 'Évaluation de la qualité de vie suite aux traitements actuels du cancer de prostate localisé', Progrès en Urologie, 23: 1100.
    https://doi.org/10.1016/j.purol.2013.08.187
84. Thompson, J., N. Lawrentschuk, M. Frydenberg, L. Thompson, and P. Stricker. 2013. 'The role of magnetic resonance imaging in the diagnosis and management of prostate cancer', BJU Int, 112 Suppl 2: 6–20.
    https://doi.org/10.1111/bju.12381
85. Birch, S. E., J. G. Kench, E. Takano, P. Chan, A. L. Chan, K. Chiam, A. S. Veillard, P. Stricker, S. Haupt, Y. Haupt, L. Horvath, and S. B. Fox. 2014. 'Expression of E6AP and PML predicts for prostate cancer progression and cancer–specific death', Ann Oncol, 25: 2392–7.
    https://doi.org/10.1093/annonc/mdu454
86. Sooriakumaran, P., A. Srivastava, S. F. Shariat, P. D. Stricker, T. Ahlering, C. G. Eden, P. N. Wiklund, R. Sanchez–Salas, A. Mottrie, D. Lee, D. E. Neal, R. Ghavamian, P. Nyirady, A. Nilsson, S. Carlsson, E. Xylinas, W. Loidl, C. Seitz, P. Schramek, C. Roehrborn, X. Cathelineau, D. Skarecky, G. Shaw, A. Warren, W. J. Delprado, A. M. Haynes, E. Steyerberg, M. J. Roobol, and A. K. Tewari. 2014. 'A multinational, multi–institutional study comparing positive surgical margin rates among 22393 open, laparoscopic, and robot– assisted radical prostatectomy patients', Eur Urol, 66: 450–6.
    https://doi.org/10.1016/j.eururo.2013.11.018
87. Thompson, J. E., S. Egger, M. Bohm, A. M. Haynes, J. Matthews, K. Rasiah, and P. D. Stricker. 2014. 'Superior quality of life and improved surgical margins are achievable with robotic radical prostatectomy after a long learning curve: a prospective single– surgeon study of 1552 consecutive cases', Eur Urol, 65: 521–31.
    https://doi.org/10.1016/j.eururo.2013.10.030
88. Thompson, J. E., D. Moses, R. Shnier, P. Brenner, W. Delprado, L. Ponsky, M. Pulbrook, M. Bohm, A. M. Haynes, A. Hayen, and P. D. Stricker. 2014. 'Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study', J Urol, 192: 67–74.
    https://doi.org/10.1016/j.juro.2014.01.014
89. Tran, M, and P. Stricker. 2014. 'An Update on the medical management of benign prostatic hypertrophy', MedicineToday, 15: 72–76.
90. Valerio, M., P. D. Stricker, H. U. Ahmed, L. Dickinson, L. Ponsky, R. Shnier, C. Allen, and M. Emberton. 2014. 'Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer', Prostate Cancer Prostatic Dis, 17: 343–7.
    https://doi.org/10.1038/pcan.2014.33
91. Gupta, R., R. O'Connell, A. M. Haynes, P. D. Stricker, W. Barrett, J. J. Turner, W. Delprado, L. G. Horvath, and J. G. Kench. 2015. 'Extraprostatic extension (EPE) of prostatic carcinoma: is its proximity to the surgical margin or Gleason score important?', BJU Int, 116: 343–50.
    https://doi.org/10.1111/bju.12911
92. Morigi, J. J., P. D. Stricker, P. J. van Leeuwen, R. Tang, B. Ho, Q. Nguyen, G. Hruby, G. Fogarty, R. Jagavkar, A. Kneebone, A. Hickey, S. Fanti, L. Tarlinton, and L. Emmett. 2015. 'Prospective Comparison of 18F–Fluoromethylcholine Versus 68Ga–PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy', J Nucl Med, 56: 1185–90.
    https://doi.org/10.2967/jnumed.115.160382
93. Rhee, H., J. H. Gunter, P. Heathcote, K. Ho, P. Stricker, N. M. Corcoran, and C. C. Nelson. 2015. 'Adverse effects of androgen–deprivation therapy in prostate cancer and their management', BJU Int, 115 Suppl 5: 3–13.
    https://doi.org/10.1111/bju.12964
94. Thompson, J. E., A. Hayen, A. Landau, A. M. Haynes, A. Kalapara, J. Ischia, J. Matthews, M. Frydenberg, and P. D. Stricker. 2015. 'Medium–term oncological outcomes for extended vs saturation biopsy and transrectal vs transperineal biopsy in active surveillance for prostate cancer', BJU Int, 115: 884–91.
    https://doi.org/10.1111/bju.12858
95. Ting, F., M. Tran, M. Böhm, A. Siriwardana, P. J. Van Leeuwen, A. M. Haynes, W. Delprado, R. Shnier, and P. D. Stricker. 2015. 'Focal irreversible electroporation for prostate cancer: functional outcomes and short–term oncological control', Prostate Cancer And Prostatic Diseases, 19: 46.
    https://doi.org/10.1038/pcan.2015.47
96. Ting, F., P. J. van Leeuwen, W. Delprado, A. M. Haynes, P. Brenner, and P. D. Stricker. 2015. 'Tumor volume in insignificant prostate cancer: Increasing the threshold is a safe approach to reduce over–treatment', Prostate, 75: 1768–73.
    https://doi.org/10.1002/pros.23062
97. Tran, M, and P. Stricker. 2015. 'An update on the medical management of prostate cancer', MedicineToday, 16: 42–48.
98. Bayliss, D., J. Duff, P. Stricker, and K. Walker. 2016. 'Decision–Making in Prostate Cancer: Active Surveillance Over Other Treatment Options', Urol Nurs, 36: 141–9.
99. Bruce, HM., P.D. Stricker, R. Gupta, R.R. Savdie, AM. Haynes, KL. Mahon, HM Lin, JG. Kench, and LG. Horvath. 2016. 'Loss of AZGP1 as a Superior Predictor of Relapse in Margin–Positive Localized Prostate Cancer', The Prostate, 76: 1491–500.
    https://doi.org/10.1002/pros.23233
100. Galvao, D. A., D. R. Taaffe, N. Spry, R. A. Gardiner, R. Taylor, G. P. Risbridger, M. Frydenberg, M. Hill, S. K. Chambers, P. Stricker, T. Shannon, D. Hayne, E. Zopf, and R. U. Newton. 2016. 'Enhancing active surveillance of prostate cancer: the potential of exercise medicine', Nat Rev Urol, 13: 258–65.
     https://doi.org/10.1038/nrurol.2016.46
101. Kalsbeek, A. M., E. F. Chan, J. Grogan, D. C. Petersen, W. Jaratlerdsiri, R. Gupta, R. J. Lyons, A. M. Haynes, L. G. Horvath, J. G. Kench, P. D. Stricker, and V. M. Hayes. 2016. 'Mutational load of the mitochondrial genome predicts pathological features and biochemical recurrence in prostate cancer', Aging (Albany NY), 8: 2702–12.
     https://doi.org/10.18632/aging.101044
102. Penzias, G., A. Janowczyk, A. Singanamalli, M.Rusu, N. Shih, M. Feldman, P. D. Stricker, W. Delprado, S. Tiwari, M. Böhm, A.M. Haynes, L. Ponsky, S.Viswanath, and A. Madabhushi. 2016. 'AutoStitcher: An Automated Program for Efficient and Robust Reconstruction of Digitized Whole Histological Sections from Tissue Fragments', Scientific Reports, 6: 29906.
     https://doi.org/10.1038/srep29906
103. Thompson, J. E., P. J. van Leeuwen, D. Moses, R. Shnier, P. Brenner, W. Delprado, M. Pulbrook, M. Bohm, A. M. Haynes, A. Hayen, and P. D. Stricker. 2016. 'The Diagnostic Performance of Multiparametric Magnetic Resonance Imaging to Detect Significant Prostate Cancer', J Urol, 195: 1428–35.
     https://doi.org/10.1016/j.juro.2015.10.140
104. Ting, F., P. J. Van Leeuwen, and P. D. Stricker. 2016. 'Step–by–Step Technique for Irreversible Electroporation of Focal Prostate Cancer: An Instructional Video Guide', J Vasc Interv Radiol, 27: 568.
     https://doi.org/10.1016/j.jvir.2016.01.003
105. Ting, F., P. J. Van Leeuwen, J. Thompson, R. Shnier, D. Moses, W. Delprado, and P. D. Stricker. 2016. 'Assessment of the Performance of Magnetic Resonance Imaging/Ultrasound Fusion Guided Prostate Biopsy against a Combined Targeted Plus Systematic Biopsy Approach Using 24–Core Transperineal Template Saturation Mapping Prostate Biopsy', Prostate Cancer, 2016: 3794738.
     https://doi.org/10.1155/2016/3794738
106. Tran, M., J. Thompson, M. Böhm, M. Pulbrook, D. Moses, R. Shnier, P. Brenner, W. Delprado, AM. Haynes, R. Savdie, and P. Stricker. 2016. 'Combination of multiparametric MRI and transperineal template‐guided mapping biopsy ofthe prostate to identify candidates for hemi‐ablative focal therapy', BJU International, 117: 48–54.
     https://doi.org/10.1111/bju.13090
107. van Leeuwen, P. J., A. Siriwardana, M. Roobol, F. Ting, D. Nieboer, J. Thompson, W.Delprado, A.M. Haynes, P. Brenner, and P. Stricker. 2016. 'Predicting Low–Risk Prostate Cancer from Transperineal Saturation Biopsies', Prostate Cancer, 2016: 7.
     https://doi.org/10.1155/2016/7105678
108. van Leeuwen, P. J., P. Stricker, G. Hruby, A. Kneebone, F. Ting, B. Thompson, Q. Nguyen, B. Ho, and L. Emmett. 2016. '(68) Ga–PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment', BJU Int, 117: 732–9.
     https://doi.org/10.1111/bju.13397
109. Emmett, L., P. J. van Leeuwen, R. Nandurkar, M. J. Scheltema, T. Cusick, G. Hruby, A. Kneebone, T. Eade, G. Fogarty, R. Jagavkar, Q. Nguyen, B. Ho, A. M. Joshua, and P. Stricker. 2017. 'Treatment Outcomes from (68)Ga–PSMA PET/CT–Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET', J Nucl Med, 58: 1972–76.
     https://doi.org/10.2967/jnumed.117.196683
110. Ginsburg, S. B., A. Algohary, S. Pahwa, V. Gulani, L. Ponsky, H. J. Aronen, P. J. Bostrom, M. Bohm, A. M. Haynes, P. Brenner, W. Delprado, J. Thompson, M. Pulbrock, P. Taimen, R. Villani, P. Stricker, A. R. Rastinehad, I. Jambor, and A. Madabhushi. 2017. 'Radiomic features for prostate cancer detection on MRI differ between the transition and peripheral zones: Preliminary findings from a multi–institutional study', J Magn Reson Imaging, 46: 184– 93.
     https://doi.org/10.1002/jmri.25562
111. Grogan, J., R. Gupta, K. L. Mahon, P. D. Stricker, A. M. Haynes, W. Delprado, J. Turner, L. G. Horvath, and J. G. Kench. 2017. 'Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in patients undergoing radical prostatectomy with long–term follow–up', BJU Int, 120: 651–58.
     https://doi.org/10.1111/bju.13857
112. Rusu, M., A. S. Purysko, S.Verma, J. Kiechle, J.Gollamudi, S. Ghose, K.Herrmann, V. Gulani, R. Paspulati, L. Ponsky, M. Böhm, A.M. Haynes, D. Moses, R. Shnier, W. Delprado, J. Thompson, P. Stricker, and A. Madabhushi. 2017. 'Computational imaging reveals shape differences between normal and malignant prostates on MRI', Scientific Reports, 7: 41261.
     https://doi.org/10.1038/srep41261
113. Scheltema, M. J., J. I. Chang, W. van den Bos, M. Bohm, W. Delprado, I. Gielchinsky, T. M. de Reijke, J. J. de la Rosette, A. R. Siriwardana, R. Shnier, and P. D. Stricker. 2017. 'Preliminary Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Focal Therapy with Irreversible Electroporation', Eur Urol Focus.
     https://doi.org/10.1016/j.euf.2017.10.007
114. Scheltema, M. J., W. van den Bos, A. R. Siriwardana, A. M. F. Kalsbeek, J. E. Thompson, F. Ting, M. Bohm, A. M. Haynes, R. Shnier, W. Delprado, and P. D. Stricker. 2017. 'Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio–recurrent prostate cancer', BJU Int, 120 Suppl 3: 51–58.
     https://doi.org/10.1111/bju.13991
115. Siriwardana, A., J. Thompson, and P. Stricker. 2017. 'Personalising prostate cancer care. Part 1: Advances in diagnosis.', MedicineToday, 18: 29–32.
116. Siriwardana, A., J. Thompson, and P. Stricker. 2017. 'Personalising prostate cancer care. Part 2: Current treatment options', MedicineToday, 18: 28–33.
117. Siriwardana, A., J. Thompson, P. J. van Leeuwen, S. Doig, A. Kalsbeek, L. Emmett, W. Delprado, D. Wong, H. Samaratunga, A. M. Haynes, G. Coughlin, and P. Stricker. 2017. 'Initial multicentre experience of (68) gallium–PSMA PET/CT guided robot–assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited', BJU Int, 120: 673–81.
     https://doi.org/10.1111/bju.13919
118. Siriwardana, A., W van den Bos, J. Thompson, R. Shnier, and P.D. Stricker. 2017. 'The role of MRI in prostate cancer: A changing paradigm', MedicineToday, 18.
119. Symons, J., and P. Stricker. 2017. "Transperineal Prostate Biopsy." In Hinman's Atlas of Urologic Surgery. Elsevier.
120. Thompson, J., and P. Stricker. 2017. 'MRI improves cost and accuracy of prostate cancer biopsy', Nature Reviews Urology, 15: 6.
     https://doi.org/10.1038/nrurol.2017.185
121. Thompson, J. E., and P. D. Stricker. 2017. 'Diagnostic accuracy of multi–parametric MRI and transrectal ultrasound–guided biopsy in prostate cancer', Lancet, 389: 767–68.
     https://doi.org/10.1016/s0140–6736(17)30121–6
122. van den Bos, W., and P. Stricker. 2017. 'Editorial Comment', The Journal of Urology, 197: 653–54.
     https://doi.org/10.1016/j.juro.2016.09.137
123. van Leeuwen, P. J., L. Emmett, B. Ho, W. Delprado, F. Ting, Q. Nguyen, and P. D. Stricker. 2017. 'Prospective evaluation of 68Gallium– prostate–specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer', BJU Int, 119: 209–15.
     https://doi.org/10.1111/bju.13540
124. van Leeuwen, P. J., A. Hayen, J. E. Thompson, D. Moses, R. Shnier, M. Bohm, M. Abuodha, A. M. Haynes, F. Ting, J. Barentsz, M. Roobol, J. Vass, K. Rasiah, W. Delprado, and P. D. Stricker. 2017. 'A multiparametric magnetic resonance imaging–based risk model to determine the risk of significant prostate cancer prior to biopsy', BJU Int, 120: 774–81.
     https://doi.org/10.1111/bju.13814
125. Zhang, A. Y., J. S. Grogan, K. L. Mahon, K. Rasiah, P. Sved, D. R. Eisinger, J. Boulas, A. Vasilaris, S. M. Henshall, P. D. Stricker, J. G. Kench, and L. G. Horvath. 2017. 'A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer', Ann Oncol, 28: 1903–09.
     https://doi.org/10.1093/annonc/mdx247
126. Algohary, A., S. Viswanath, R. Shiradkar, S. Ghose, S. Pahwa, D. Moses, I. Jambor, R. Shnier, M. Bohm, A. M. Haynes, P. Brenner, W. Delprado, J. Thompson, M. Pulbrock, A. S. Purysko, S. Verma, L. Ponsky, P. Stricker, and A. Madabhushi. 2018. 'Radiomic features on MRI enable risk categorization of prostate cancer patients on active surveillance: Preliminary findings', J Magn Reson Imaging.
     https://doi.org/10.1002/jmri.25983
127. Emmett, L., R. Nandurkar, P. Van Leeuwen, H. Woo, R. Kooner, D. Ende, G. O’Neill, C. Yuen, B. Ho, Q. Nguyen, A. Hickey, and P. Stricker. 2018. 'Staging with Ga–68 HBED–CC–Glu–NH–CO–NH–Lys (Ahx) PSMA–11 PET CT (PSMA) prior to radical prostatectomy has high predictive value in assessing biochemical response to surgery', European Urology Supplements, 17: e1903.
     https://doi.org/10.1016/S1569–9056(18)32310–8
128. Kalsbeek, A. M. F., E. K. F. Chan, J. Grogan, D. C. Petersen, W. Jaratlerdsiri, R. Gupta, R. J. Lyons, A. M. Haynes, L. G. Horvath, J. G. Kench, P. D. Stricker, and V. M. Hayes. 2018. 'Altered mitochondrial genome content signals worse pathology and prognosis in prostate cancer', Prostate, 78: 25–31.
     https://doi.org/10.1002/pros.23440
129. Lin, H. M., B. Y. Lee, L. Castillo, C. Spielman, J. Grogan, N. K. Yeung, J. G. Kench, P. D. Stricker, A. M. Haynes, M. M. Centenera, L. M. Butler, S. M. Shreeve, L. G. Horvath, and R. J. Daly. 2018. 'Effect of FAK inhibitor VS–6063 (defactinib) on docetaxel efficacy in prostate cancer', Prostate, 78: 308–17.
     https://doi.org/10.1002/pros.23476
130. Mahon, K. L., P.Stricker, J. Kench, J. Grogan, W. Delprado, J. Turner, L. Horvath, and D. I. Quinn. 2018. 'P53 as a predictor of clinical outcome in localized prostate cancer', Journal of Clinical Oncology, 36: 57–57.
     https://doi.org/10.1200/JCO.2018.36.6_suppl.57
131. Nair, S.S., PL. Luu, W. Qu, M. Maddugoda, L. Huschtscha, R. Reddel, G. Chenevix–Trench, M. Toso, J. G. Kench, L.G. Horvath, V. M. Hayes, P. Stricker, T.P. Hughes, D.L. White, J.E. J. Rasko, J.J–L Wong, and S.J. Clark. 2018. 'Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X Ten', Epigenetics & Chromatin, 11: 24.
     https://doi.org/10.1186/s13072–018–0194–0
132. Pidsley, R., M. G. Lawrence, E. Zotenko, B. Niranjan, A. Statham, J. Song, R. M. Chabanon, W. Qu, H. Wang, M. Richards, S. S. Nair, N. J. Armstrong, H. T. Nim, M. Papargiris, P. Balanathan, H. French, T. Peters, S. Norden, A. Ryan, J. Pedersen, J. Kench, R. J. Daly, L. G. Horvath, P. Stricker, M. Frydenberg, R. A. Taylor, C. Stirzaker, G. P. Risbridger, and S. J. Clark. 2018. 'Enduring epigenetic landmarks define the cancer microenvironment', Genome Research, 28: 625–38.
     https://doi.org/10.1101/gr.229070.117
133. Roach, P. J., R. Francis, L. Emmett, E. Hsiao, A. Kneebone, G. Hruby, T. Eade, Q. A. Nguyen, B. D. Thompson, T. Cusick, M. McCarthy, C. Tang, B. Ho, P. D. Stricker, and A. M. Scott. 2018. 'The Impact of (68)Ga–PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study', J Nucl Med, 59: 82–88.
     https://doi.org/10.2967/jnumed.117.197160
134. Scheltema, M. J., J. I. Chang, M. Bohm, W. van den Bos, A. Blazevski, I. Gielchinsky, A. M. F. Kalsbeek, P. J. van Leeuwen, T. V. Nguyen, T. M. de Reijke, A. R. Siriwardana, J. E. Thompson, J. J. de la Rosette, and P. D. Stricker. 2018. 'Pair–matched patient–reported quality of life and early oncological control following focal irreversible electroporation versus robot–assisted radical prostatectomy', World J Urol.
     https://doi.org/10.1007/s00345–018–2281–z
135. Thompson, J. E., S. Egger, M. Bohm, A. R. Siriwardana, A. M. Haynes, J. Matthews, M. J. Scheltema, and P. D. Stricker. 2018. 'Superior Biochemical Recurrence and Long–term Quality–of–life Outcomes Are Achievable with Robotic Radical Prostatectomy After a Long Learning Curve–Updated Analysis of a Prospective Single–surgeon Cohort of 2206 Consecutive Cases', Eur Urol, 73: 664–71.
     https://doi.org/10.1016/j.eururo.2017.11.035
136. van den Bos, W., M. J. Scheltema, A. R. Siriwardana, A. M. F. Kalsbeek, J. E. Thompson, F. Ting, M. Bohm, A. M. Haynes, R. Shnier, W. Delprado, and P. D. Stricker. 2018. 'Focal irreversible electroporation as primary treatment for localized prostate cancer', BJU Int, 121: 716–24.
     https://doi.org/10.1111/bju.13983
137. Zhang, A. Y., K. Chiam, Y. Haupt, S. B. Fox, S. Birch, W.Tilley, L. Butler, K. E. Knudsen, C. Cornstock, K. Rasiah, J. Grogan, K.L. Mahon, T. Bianco–Miotto, M. Bohm, S. M. Henshall, W. Delprado, P. Stricker, L. Horvath, and J. Kench. 2018. 'An analysis of multiple biomarkers to better predict prostate cancer metastasis and death after radical prostatectomy', Journal of Clinical Oncology, 36: 54–54.
     https://doi.org/10.1200/JCO.2018.36.6_suppl.54
138. Jaratlerdsiri, W., E. K. F. Chan, T. Gong, D. C. Petersen, A. M. F. Kalsbeek, P. A. Venter, P. D. Stricker, M. R. Bornman, and V. M. Hayes. 2018. 'Whole Genome Sequencing Reveals Elevated Tumor Mutational Burden and Initiating Driver Mutations in African Men with Treatment–Naive, High–Risk Prostate Cancer', Cancer Res.
     https://doi.org/10.1158/0008–5472.can–18–0254
139. Gielchinsky, I., M. J. Scheltema, T. Cusick, J. Chang, R. Shnier, D. Moses, W. Delprado, Q. Nguyen, C. Yuen, A. M. Haynes, and P. D. Stricker. 2018. 'Reduced sensitivity of multiparametric MRI for clinically significant prostate cancer in men under the age of 50', Res Rep Urol, 10:
     https://doi.org/10.2147/RRU.S169017
140. Gielchinsky, I., J. Chang, T. Cusick, W. Delprado, Q. Nguyen, C. Yuen, R. Savdie, M. Bohm, A. M. Haynes, M. J. Scheltema, and P. D. Stricker. 2018. 'Prostate cancer in 432 men aged <50 years in the prostate–specific antigen era: a new outlook', BJU Int.
     https://doi.org/10.1111/bju.14586
141. Scheltema, M. J., J. I. Chang, W. van den Bos, I. Gielchinsky, T. V. Nguyen, T. M. Reijke, A. R. Siriwardana, M. Bohm, J. J. de la Rosette, and P. D. Stricker. 2018. 'Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments', Diagn Interv Radiol, 24: 268–75.
     https://doi.org/10.5152/dir.2018.17374
142. Penzias, G., A. Singanamalli, R. Elliott, J. Gollamudi, N. Shih, M. Feldman, P. D. Stricker, W. Delprado, S. Tiwari, M. Bohm, A. M. Haynes, L. Ponsky, P. Fu, P. Tiwari, S. Viswanath, and A. Madabhushi. 2018. 'Identifying the morphologic basis for radiomic features in distinguishing different Gleason grades of prostate cancer on MRI: Preliminary findings', PLoS One, 13: e0200730.
     https://doi.org/10.1371/journal.pone.0200730
143. Thompson, J. E., and P. D. Stricker. 2018. 'MRI improves active surveillance of prostate cancer however biopsy is still crucial', BJU Int, 122: E1–E2.
     https://doi.org/10.1111/bju.14424
144. Zhang, A. Y., K. Chiam, Y. Haupt, S. Fox, S. Birch, W. Tilley, L. M. Butler, K. Knudsen, C. Comstock, K. Rasiah, J. Grogan, K. L. Mahon, T. Bianco–Miotto, C. Ricciardelli, M. Bohm, S. Henshall, W. Delprado, P. Stricker, L. G. Horvath, and J. G. Kench. 2018. 'An Analysis of a Multiple Biomarker Panel to Better Predict Prostate Cancer Metastasis After Radical Prostatectomy', Int J Cancer.
     https://doi.org/10.1002/ijc.31906
145. van Leeuwen, P. J., M. Donswijk, R. Nandurkar, P. Stricker, B. Ho, S. Heijmink, E. M. K. Wit, C. Tillier, E. van Muilenkom, Q. Nguyen, H. G. van der Poel and L. Emmett (2018). "68Ga PSMA PET/CT predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate and high–risk prostate cancer." BJU Int.
     https://doi.org/10.1111/bju.14506
146. Nandurkar, R., P. van Leeuwen, P. Stricker, H. Woo, R. Kooner, C. Yuen, G. O'Neill, D. Ende, T. Cusick, B. Ho, A. Hickey and L. Emmett (2019). "(68)Ga–HBEDD PSMA–11 PET/CT staging prior to radical prostatectomy in prostate cancer patients: Diagnostic and predictive value for the biochemical response to surgery." Br J Radiol 92(1095): 20180667.
     https://doi.org/10.1259/bjr.20180667
147. Emmett, L., M. Crumbaker, B. Ho, K. Willowson, P. Eu, L. Ratnayake, R. Epstein, A. Blanksby, L. Horvath, A. Guminski, K. Mahon, C. Gedye, C. Yin, P. Stricker and A. M. Joshua (2019). "Results of a Prospective Phase 2 Pilot Trial of (177)Lu–PSMA–617 Therapy for Metastatic Castration–Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression." Clin Genitourin Cancer 17(1): 15–22.
     https://doi.org/10.1016/j.clgc.2018.09.014
148. van Leeuwen, P. J., L. Emmett, M. L. Donswijk, P. D. Stricker, F. J. Pos, E. M. K. Wit and H. G. van der Poel (2019). 'Early outcomes after [68Ga]PSMA–PET/CT guided salvage therapy in men with biochemical recurrence after radical prostatectomy | [Vroege oncologische uitkomsten van [68Ga]PSMA–PET/CT–gestuurde salvagetherapie bij mannen met biochemisch recidief na radicale prostatectomie]' Tijdschrift voor Urologie 9(1): 2–8.
     https://doi.org/10.1007/s13629–018–00215–w
149. Bancroft, E. K., S. Saya, E. C. Page, K. Myhill, S. Thomas, J. Pope, A. Chamberlain, R. Hart, W. Glover, J. Cook, D. J. Rosario, B. T. Helfand, C. Hutten Selkirk, R. Davidson, M. Longmuir, D. M. Eccles, N. Gadea, C. Brewer, J. Barwell, M. Salinas, L. Greenhalgh, M. Tischkowitz, A. Henderson, D. G. Evans, S. S. Buys, R. A. Eeles, IMPACT Collaborators* and N. K. Aaronson (2019). "Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations." BJU Int 123(2): 284–292.
     https://doi.org/10.1111/bju.14412 *Stricker, P. D. is an author under the IMPACT Collaborators
150. Scheltema, M. J., J. I. Chang, P. D. Stricker, P. J. van Leeuwen, Q. A. Nguyen, B. Ho, W. Delprado, J. Lee, J. E. Thompson, T. Cusick, A. S. Spriensma, A. R. Siriwardana, C. Yuen, R. Kooner, G. Hruby, G. O'Neill and L. Emmett (2019). "Diagnostic accuracy of (68) Ga– prostate–specific membrane antigen (PSMA) positron–emission tomography (PET) and multiparametric (mp)MRI to detect intermediate–grade intra–prostatic prostate cancer using whole– mount pathology: impact of the addition of (68) Ga–PSMA PET to mpMRI." BJU Int.
     https://doi.org/10.1111/bju.14794
151. Scheltema, M. J., T. J. O'Brien, W. van den Bos, D. M. de Bruin, R. V. Davalos, C. W. M. van den Geld, M. P. Laguna, R. E. Neal, 2nd, I. M. Varkarakis, A. Skolarikos, P. D. Stricker, T. M. de Reijke, C. B. Arena and J. de la Rosette (2019). "Numerical simulation modeling of the irreversible electroporation treatment zone for focal therapy of prostate cancer, correlation with whole–mount pathology and T2–weighted MRI sequences." Ther Adv Urol 11: 1756287219852305.
     https://doi.org/10.1177/1756287219852305
152. Feng, Y., W. Jaratlerdsiri, S. M. Patrick, R. J. Lyons, A. M. Haynes, C. C. Collins, P. D. Stricker, M. S. R. Bornman and V. M. Hayes (2019). "Metagenomic analysis reveals a rich bacterial content in high– risk prostate tumors from African men." Prostate 79(15): 1731–1738.
     https://doi.org/10.1002/pros.23897
153. Quinn, D. I., P. D. Stricker, J. G. Kench, J. Grogan, A. M. Haynes, S. M. Henshall, J. J. Grygiel, W. Delprado, J. J. Turner, L. G. Horvath and K. L. Mahon (2019). "p53 nuclear accumulation as an early indicator of lethal prostate cancer." Br J Cancer 121(7): 578–583.
     https://doi.org/10.1038/s41416–019–0549–8
154. Emmett, L., R. Tang, R. H. Nandurkar, G. Hruby, P. J. Roach, J. A. Watts, T. Cusick, A. Kneebone, B. Ho, L. Chan, P. van Leeuwen, M. Scheltema, A. Nguyen, C. Yin, A. Scott, C. Tang, M. McCarthy, K. Fullard, M. Roberts, R. Francis and P. Stricker (2019). "3–year freedom from progression following (68)GaPSMA PET CT triaged management in men with biochemical recurrence post radical prostatectomy. Results of a prospective multi–center trial." J Nucl Med.
     https://doi.org/10.2967/jnumed.119.235028
155. Lam, T. B. L., S. MacLennan, P. M. Willemse, M. D. Mason, K. Plass, R. Shepherd, R. Baanders, C. H. Bangma, A. Bjartell, A. Bossi, E. Briers, A. Briganti, K. T. Buddingh, J. W. F. Catto, M. Colecchia, B. W. Cox, M. G. Cumberbatch, J. Davies, N. F. Davis, M. De Santis, P. Dell'Oglio, A. Deschamps, J. F. Donaldson, S. Egawa, C. D. Fankhauser, S. Fanti, N. Fossati, G. Gandaglia, S. Gillessen, N. Grivas, T. Gross, J. P. Grummet, A. M. Henry, A. Ingels, J. Irani, M. Lardas, M. Liew, D. W. Lin, L. Moris, M. I. Omar, K. H. Pang, C. C. Paterson, R. Renard–Penna, M. J. Ribal, M. J. Roobol, M. Roupret, O. Rouviere, G. Sancho Pardo, J. Richenberg, I. G. Schoots, J. P. M. Sedelaar, P. Stricker, D. Tilki, S. Vahr Lauridsen, R. C. N. van den Bergh, T. Van den Broeck, T. H. van der Kwast, H. G. van der Poel, G. van Leenders, M. Varma, P. D. Violette, C. J. D. Wallis, T. Wiegel, K. Wilkinson, F. Zattoni, J. M. O. N'Dow, H. Van Poppel, P. Cornford and N. Mottet (2019). "EAU–EANM–ESTRO–ESUR–SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study)." Eur Urol.
     https://doi.org/10.1016/j.eururo.2019.09.020
156. Blazevski, A., M. J. Scheltema, A. Amin, J. E. Thompson, N. Lawrentschuk and P. D. Stricker (2019). "Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment." BJU Int.
     https://doi.org/10.1111/bju.14951
157. Amin, A., M. J. Scheltema, R. Shnier, A. Blazevski, D. Moses, T. Cusick, A. Siriwardena, B. Yuen, P. J. v. Leeuwen, A. M. Haynes, J. Matthews, P. Brenner, G. O'Neill, C. Yuen, W. Delprado, P. Stricker and J. Thompson (2020) "The MRI in Active Surveillance (MRIAS); Trial: Use of Baseline mpMRI and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate Biopsies.". Journal of Urology 0(0):10.1097/JU.0000000000000693.
     https://doi.org/10.1097/JU.0000000000000693
158. Blazevski, A., M. J. Scheltema, A. Amin, J. E. Thompson, N. Lawrentschuk and P. D. Stricker (2020). "Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment." BJU Int 125(3): 369–378.
     https://doi.org/10.1111/bju.14951
159. Luiting, H. B., P. J. van Leeuwen, M. B. Busstra, T. Brabander, H. G. van der Poel, M. L. Donswijk, A. N. Vis, L. Emmett, P. D. Stricker and M. J. Roobol (2020). "Use of gallium–68 prostate–specific membrane antigen positron–emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature." BJU Int 125(2): 206–214.
     https://doi.org/10.1111/bju.14944
160. Crumbaker, M., E. K. F. Chan, T. Gong, N. Corcoran, W. Jaratlerdsiri, R. J. Lyons, A. M. Haynes, A. A. Kulidjian, A. M. F. Kalsbeek, D. C. Petersen, P. D. Stricker, C. A. M. Jamieson, P. I. Croucher, C. M. Hovens, A. M. Joshua and V. M. Hayes (2020). "The Impact of Whole Genome Data on Therapeutic Decision–Making in Metastatic Prostate Cancer: A Retrospective Analysis." Cancers (Basel) 12(5).
     https://doi.org/10.3390/cancers12051178 .
161. Algohary, A., R. Shiradkar, S. Pahwa, A. Purysko, S. Verma, D. Moses, R. Shnier, A. M. Haynes, W. Delprado, J. Thompson, S. Tirumani, A. Mahran, A. R. Rastinehad, L. Ponsky, P. D. Stricker and A. Madabhushi (2020). "Combination of Peri–Tumoral and Intra– Tumoral Radiomic Features on Bi–Parametric MRI Accurately Stratifies Prostate Cancer Risk: A Multi–Site Study." Cancers (Basel) 12(8).
     https://doi.org.au/10.3390/cancers12082200 .
162. Blazevski A, Amin A, Scheltema MJ, Balakrishnan A, Haynes AM, Barreto D, Cusick T, Thompson J, Stricker PD. “Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE).” World Journal of Urology. 2020 Jun 2:1–8.
     http://doi.org.au/10.1007/s00345–020–03275–z

Books, Chapters and DVDs

1995 – Tumour Markers and Flow Cytometry. Chapter in book "The Bladder". Fitzpatrick and Krane. Chapter by P.Stricker and P.Russell. Pg 385–394.

2000 – The Australian Medical Association. "Home Medical Guide to Prostate Disorders". Consulting Editor.

2003 – "Treatment of Localised Prostate Cancer". Member of the Prostate Cancer Working for Cancer Network Australia.

2004 – "PSA for the General Practitioner" Book. P.Stricker and K. Phelps.

2008 – "Prostate Cancer for the General Practitioner." Book P. Stricker and K.Phelps.

2008 – "So I Have Prostate Cancer, What Now?" PCFA DVD

2009 – "How Do You Choose" DVD. P Stricker

2010 – "Intergrative Medicine for the General Practitioner" Book. Hassad and Phelps. Chapter on prostate cancer.

2012 – Series of DVD’s – P Stricker.

“Pelvic Floor Exercises, Moving Forward”,

“Prevention & Localised Prostate Cancer”,

“Advanced Prostate Cancer & Hormone Treatments”,

“Cured of Prostate Cancer – What About Quality of Life”,

“Return to Potency after Prostate Cancer”,

“Prostate Cancer Treatments – Managing Side Effects”,

“Prostate Cancer – Integrative Medicine Taking Control”,

“Prostate Cancer – Urinary Control”,

“Advanced Prostate Cancer” – Prof. Charles Myers,

“Prostate Cancer – managing the Mind”,

“Robotic Surgery – The Journey”.

2013 – “Improving outcomes in robotic radical prostatectomy.” Chapter 7. Editor Vip Patel.

2014–15 – “Clinical Practice Guidelines for PSA Testing & Early Management of Test–Detected Prostate Cancer” Prostate Cancer Foundation of Australia & Cancer Council Australia. NHMRC approved. Part of the expert advisory panel

2018 – Early detection and screening for prostate cancer. Chapter in the book “Evidence–Based Urology”, 2nd Edition. Dahm and Dmochowski. Pgs. 257–265. Chapter by P. van Leeuwen, M.J. Roobol and P.D. Stricker.

2019 – Urology Fellowship Handbook: A Concise Guide to Clinical Urology.

Chapter in the book as co–author with other urologists, Chapter 18–20,

Pgs 606. Authors Matthew Winter and Venu Chalasani

Symposia Convened (National and International)

1. Impotence Symposium of Australasia – Operative Workshop St Vincent's Hospital – 1991. Editor of Monograph. Presentations on "Intracorporeal Pharmacotherapy – Results and Complications" – P. Stricker (T.Dean) & "Polypharmacotherapy" – P.Stricker (L.Jacobs) Convener

2. Update of Urology for GP's University of NSW 1993. Presentations on Renal calculi, Prostate cancer & Impotence Convener

3. Society Internationale d'Urologie 23rd Congress Meeting Sydney. 1994. Editor of daily proceedings & Presenter

4. Prostate Cancer Symposium – Operative Workshop St Vincent's Clinic 1995. Editor of Monograph. Presentation on "Radical Perineal Prostatectomy – St Vincent's Experience". Convener

5. Impotence Management Symposia. P Stricker – Chairman of Australian Impotence Advisory Board 1995

6. Australian Society of Impotence Medicine Inaugural Meeting 1997. 4 Presentations & Surgical Workshop Co Convener

7. Inaugural National GUOG Meeting (Leura). Presentations & Workshop on Prostate Cancer Surgery Co Convener

8. Brachytherapy for Prostate Cancer Symposium with J.Blasko St Vincent's Hospital. 1997 Convener and Demonstrated

9. Prostate Cancer Symposium – Presentation on Radical Prostatectomy Garvan Institute. 1999 Convener

10. Benign Prostatic Hypertrophy – Laser Prostatectomy St Vincent's Hospital. 1999 Co Convener

11. Prostate Cancer Update with Peter Scardino – Operative Workshop St Vincent's Hospital. 2001 Convener

12. Laparoscopic Radical Prostatectomy – Operative Workshop St Vincent's Hospital. 2003 Convener R.Kooner & P.Stricker

13. Brachytherapy Workshop with Michael Zelefsky – Operative Workshop St Vincent's Hospital 2005. Convener

14. Robot Assisted Radical Prostatectomy with Vip Patel – Operative Workshop St Vincent's Hospital 2007. Convener.

15. MRI of the Prostate – A Multidisciplinary Symposium – May 2012. Co– convener.

16. Focal Therapy, Imaging & Biopsy Techniques with Mark Emberton Operative Workshop St Vincent’s Hospital, 2013. Convener.

Presentations (National and International)

From 2013 onwards

1. Beattie K and Stricker P. Prevalence of high–risk features in radical prostatectomy specimens in patients who met criteria for nerve– sparing radical prostatectomy. Oral presentation at the Urological Society of Australia and New Zealand (USANZ) NSW section meeting. 9–12 Nov 2013, Hamilton Island, Australia

2. Thompson J and Stricker P. Comparison between the accuracy of 12, 16 and 20 core TRUS biopsy in detecting significant prostate cancer and correlation with grade and location on radical prostatectomy. Oral presentation at the Urological Society of Australia and New Zealand (USANZ) NSW section meeting. 9–12 Nov 2013, Hamilton Island, Australia

3. Thompson J and Stricker P. Superior Quality of Life and Improved Surgical Margins Are Achievable with Robotic Radical Prostatectomy After a Long Learning Curve: A Prospective Single– surgeon Study of 1552 Consecutive Cases. Oral presentation at the Urological Society of Australia and New Zealand (USANZ) NSW section meeting. 9–12 Nov 2013, Hamilton Island, Australia

4. Tran M, Jackson B, Boehm M, Haynes A–M, Stricker P, Irreversible Electroporation for Focal Prostate Cancer: Safety, Short–term Functional and Oncological Outcomes. Poster Presentation. 68th Urological Society of Australia and New Zealand Annual Scientific Meeting 11th – 19th April 2015, Adelaide, South Australia

5. Tiwari S, Haynes A–M, Nguyen Q, Hammond G, Kench JG, Horvath LG, Stricker PD. A Prostate Cancer Biorepository meeting International Collaborative Demands. Poster Presentation. International Society for Biological and Environmental Repositories (ISBER) 2015 Annual Meeting and Exhibits 5–9 May 2015, Phoenix Arizona, USA

6. Tiwari S, Haynes A–M, Nguyen Q, Hammond G, Kench JG, Horvath LG, Stricker PD. The Garvan Query Application (GQA): A Comprehensive Search Engine for a Prostate Cancer Biorepository. Poster Presentation. International Society for Biological and Environmental Repositories (ISBER) 2015 Annual Meeting and Exhibits 5– 9 May 2015, Phoenix Arizona, USA

7. Thompson J, Shnier R, Moses D, Brenner P, Delprado W, Tran M, Ponsky L, Boehm M, Hayen A, Stricker P. Oral Presentation. Prospective study of pre–biopsy multiparametric magnetic resonance imaging (mpMRI) compared to transperineal template mapping biopsy (TTMB) for detection of clinically significant prostate cancer: is it accurate enough to guide selection of men for biopsy? Oral Presentation. American Urological Association Annual Meeting 15–19 May 2015, New Orleans, Louisiana, USA

8. Tran M, Thompson J, Boehm M, Pulbrook M, Moses D, Shnier R, Brenner P, Delprado W, Haynes A–M, Savdie R, Stricker P. Combination of multi–parametric magnetic resonance imaging (mp–MRI) and transperineal template–guided mapping biopsy (TTMB) of the prostate to identify candidates for hemi–ablative focal therapy. Poster Presentation. American Urological Association Annual Meeting 15–19 May 2015, New Orleans, Louisiana, USA

9. Algohary A, Viswanath S, Prasanna P, Pahwa S, Gulani V, Moses D, Shnier R, Böhm M, Haynes A–M, Brenner P, Delprado W, Thompson J, Pulbrock M, Stricker P, Ponsky L, Madabhushi A. Quantitative assessment of T2–weighted MRI to better identify patients with prostate cancer in a screening population. Poster Presentation. American Urological Association Annual Meeting 15–19 May 2015, New Orleans, Louisiana, USA

10. Stricker PD. The role of focal therapy in localized prostate cancer, preliminary Australian results. Invited speaker. American Urological Association Annual Meeting 15–19 May 2015, New Orleans, Louisiana, USA

11. Stricker PD. Focal Therapy for Prostate Cancer Debate. Annual Meeting 15–19 May 2015, New Orleans, Louisiana, USA

12. Stricker PD. MRI nanogram for prostate cancer. Invited speaker. 16th Asia–Pacific Prostate Cancer Conference. Cairns Australia

13. Haynes A–M, Tiwari S, Nguyen Q, Abuodha M, Stricker P and Horvath L. The Pros and Cons of moving towards a modern method for the storage of blood samples in a research biorepository. Poster Presentation. International Society for Biological and Environmental Repositories (ISBER). 5–8 April 2016 Berlin, Germany

14. Siriwardana A, van Leeuwen PJ, Roobol M, Ting F, Nieboer D, Thompson J, Delprado W, Haynes A, Brenner P, and Stricker P. Predicting low–risk prostate cancer from transperineal saturation biopsies. USANZ 2016 Annual Scientific Meeting 16–19th April 2016, Gold Coast, Australia.

15. Siriwardana A, van Leeuwen PJ, Roobol M, Ting F, Nieboer D, Thompson J, Delprado W, Haynes A, Brenner P, and Stricker P. Predicting low–risk prostate cancer from transperineal saturation biopsies. American Urological Association Annual Meeting 2016 – 6–10th May, 2016. San Diego, USA.

16. Stricker PD. Nanoknife focal therapy. Invited speaker. 3rd Friends of Israel Urological Symposium 5–7th July 2016. Tel–Aviv, Israel.

17. Stricker PD. Surgery is better than radiotherapy debate. Invited speaker. 3rd Friends of Israel Urological Symposium 5–7th July 2016. Tel–Aviv, Israel.

18. Nguyen Q, Haynes AM, Horvath L and Stricker PD. Prostate Cancer Research: From Lab Bench to Beside: A prospective from the Trenches. Poster presentation. 9th Health Services and Policy Research Conference 7 – 9th Dec 2015. Melbourne, Australia

19. Nguyen Q, Stricker PD, Thompson B and Emmett L. Evaluating changes in clinical management following the introduction of Ga68–PSMA PET scans for the detection of prostate cancer. Poster presentation. Health Services Research United Kingdom (HSRUK) Symposium. 13–14 July 2016. Nottingham, United Kingdom

20. Van den Bos W, Stricker PD et al. Focal Therapy Using IRE in prostate cancer. Synergy Miami, November 2016. Miami Beach, Florida USA.

21. Siriwardana A, van den Bos W, Kalsbeek A, Thompson J, Ting F, Boehm M, Haynes A, Shnier R, Delprado W and Stricker PD. Focal Irreversible Electroporation (IRE) as a primary and salvage treatment for localised prostate cancer. USANZ 2017 Annual Scientific Meeting 24–27th February 2017, Canberra, Australia

22. Siriwardana A, Thompson J, Hayen A, Ting F, Delprado W, Brenner P, Ende D, Kooner R, O’Neill G, Yuen C, Tiwari S, Haynes A and Stricker P. Lymph node yield at radical prostatectomy is a predictor of biochemical recurrence–free survival (BFS) in high–risk prostate cancer patients. USANZ 2017 Annual Scientific Meeting 24–27th February 2017, Canberra, Australia

23. Siriwardana A, Thompson J, Doig S, Kalsbeek A, Emmett L, Delprado W, Wong D, Samaratunga H, Haynes A, Couglin G and Stricker PD. Robot–assisted Salvage Node Dissection For Oligometastatic Nodal Disease Detected By 68Gallium–PSMA PET/CT: A Multicentre Retrospective Series. USANZ 2017 Annual Scientific Meeting 24–27th February 2017, Canberra, Australia 2017 Keith Kirkland Prize Awarded

24. Stricker PD. My learning curve and improving patients erectile function recovery. Invited speaker. Sydney Robotic Summit: Research and Innovation. 24th June 2017 Sydney Australia.

25. Thompson JE, Egger S, Bohm M, Siriwardana A, Haynes AM, Matthews J, Scheltema M, Stricker PD. Superior biochemical recurrence and quality of life outcomes are achievable with robotic radical prostatectomy versus open radical prostatectomy – update of a prospective single–surgeon study of 2206 consecutive cases. 5th Global Congress on Prostate Cancer. 28 – 30 June 2017, Lisbon Portugal

26. Scheltema, MJ, van den Bos W, Siriwardana AR, Kalsbeek AMF. Thompson JE, Ting F, Bohm M, Haynes AM, Shnier R, Delprado W, Stricker PD. Focal Irreversible Electroporation as primary and salvage treatment for prostate cancer. 5th Global Congress on Prostate Cancer. 28 – 30 June 2017, Lisbon Portugal

27. Scheltema MJ, Chang JI, van den Bos, Bohm M, Delprado W, Gielchinsky I, de Reijke TM, de la Rosette J, Sirawardana AR, Shnier R, Stricker PD. Diagnostic Accuracy of Mulitparametric Resonance Imaging Following Prostate Cancer Focal Therapy with Irreversible Electroporation. 93rd Annual Meeting Western Section of the American Urological Association, 6 –10 August 2017, Vancouver British Columbia Canada

28. Scheltema MJ, Chang JI, van den Bos, Gielchinsky I, de Reijke TM, Sirawardana AR, Bohm M, de la Rosette J, Stricker PD. Genito– Urinary Function and Quality of Life after Focal Irreversible Electroporation of Different Prostate Segments. 93rd Annual Meeting Western Section of the American Urological Association, 6 –10 August 2017, Vancouver British Columbia Canada

29. Scheltema MJ, Chang JI, Bohm B, van den Bos W, Gielchinsky I, Kalsbeek AF, van Leeuwen PJ, de Reijke TM, Siriwardana AR, de la Rosette JJ. Stricker PD. Pair–matched Patient–reported Quality of Life following Focal Irreversible Electroporation versus Robot– assisted Radical Prostatectomy. 37th Congress of the Societe Internationale d’Urologie. 19–22 October 2017, Lisbon Portugal.

30. Chang J, Stricker PD Emmett L et al. False positive intraprostatic lesions on 68Ga Positron emission tomography in an intermediate prostate cancer cohort: Description of a benign cystic cellular pattern with intense PSMA activity. For Poster Presentation at USANZ 2018 in Melb 24–27th of February 2018.

31. Blazevski A, Yuen B, Scheltema MJ, Chang J, Masand N, Haynes AM, Nguyen Q, Stricker P. Is it time for prostate cancer’s lumpectomy? Focal irreversible electroporation (IRE) for localised clinically significant prostate cancer. 26th ASMR NSW ASM 2018

32. Blazevski A, Pidsley R, Qu W, Norbie D, Luu L, Chang J, Yuen B, Scheltema MJ, Masand N, Haynes AM, Nguyen Q, Stirzaker C, Song J, Stricker P, Clark S. When Focal Therapy Fails for Localised Prostate Cancer – Can Epigenetics Predict Which Patients Fail and Improve Patient Selection? ANZUP ASM 8 – 10 July 2018. Sydney, Australia.

33. Blazevski A, Yuen B, Scheltema MJ, Chang J, Masand N, Haynes AM, Nguyen Q, Stricker P. Focal irreversible electroporation as salvage treatment for localised radio–recurrent prostate cancer – Initial results and initiation of the FIRE trial. ANZUP ASM 8 – 10 July 2018. Sydney, Australia.

34. Stricker P, Blazevski A, Scheltema MJ, Thompson J, Haynes AM, Nyguen Q, Chang, J, Yuen B. Oncological outcomes of irreversible electroporation (Nanoknife) for localised clinically significant prostate cancer at single Australia centre. 6th Edition Global Congress on Prostate Cancer (PROSCA 2018). 28 – 30 June 2018. Frankfurt, Germany

35. Blazevski A, Yuen B, Scheltema MJ, Chang J, Masand N, Haynes AM, Nguyen Q, Stricker P. Is it time for prostate cancer’s lumpectomy? – Focal irreversible electroporation (IRE) for localised clinically significant prostate cancer. ASMR NSW Annual Scientific Meeting, June 2018. Sydney, Australia.

36. Blazevski A, Yuen B, Scheltema MJ, Chang K, Masand N, Haynes AM, Nguyen Q, Stricker P. 5 years of Irreversible Electroporation (Nanoknife) for Localised Prostate Cancer. Asia–Pacific Prostate Conference 2018. Brisbane, Australia.

37. Blazevski A, Yuen B, Mare A. Retrospective Multicentre Cohort Study of Urothelial Manipulating Investigations and their Effects on Recurrence and Oncological Outcome for Upper Tract Urothelial Carcinoma. 38th Congress of the Société Internationale d’Urologie. 4 – 7 October 2018. Seoul, Korea

38. Blazevski A, Yuen B, Scheltema MJ, Masand N, Haynes AM, Nguyen Q, Stricker P. Oncological Outcomes of Focal Irreversible Electroporation as Primary Treatment for Clinically Significant Localised Prostate Cancer. 38th Congress of the Société Internationale d’Urologie. 4 – 7 October 2018. Seoul, Korea

39. Blazevski A, Yuen B, Scheltema MJ, Masand N, Haynes AM, Nguyen Q, Stricker P. Application of the IDEAL Framework to the Introduction of a Novel Treatment for Localised Clinically Significant Prostate Cancer. 38th Congress of the Société Internationale d’Urologie. 4 – 7 October 2018. Seoul, Korea

40. Blazevski A, Stricker P. Where is the prostate cancer recurrence after radiation therapy? Implications for biopsy and focal salvage therapy. USANZ NSW Section Meeting. 1 – 3 November 2018. Cypress Lakes, Hunter Valley, NSW, Australia.

41. Blazevski A. Irreversible Electroporation (Nanoknife) for Localised Clinically Significant Prostate Cancer. Peter MacCallum Cancer Centre – Uro–Oncology Meeting July 2018. Melbourne, Victoria.

42. Blazevski A, Stricker P. Reduced Sensitivity of Multiparametric MRI for Clinically Significant Prostate Cancer in Men Under the Age of 50 – ACT RACS Annual Scientific Meeting 2018.

43. Blazevski A, Scheltema MJ, Yuen B, Masand N, Haynes AM, Cusick T, Stricker P. Salvage Irreversible Electroporation for Locally Recurrent Prostate Cancer after Radiotherapy – Oncological and Functional Outcomes. USANZ Annual Scientific Meeting 2019. Brisbane, Queensland

44. Blazevski A, Scheltema MJ, Yuen B, Masand N, Haynes AM, Cusick T, Stricker P. Update on 12–Month Biopsy Proven Oncological and Functional Outcomes of Primary Irreversible Electroporation for Localised Prostate Cancer. USANZ Annual Scientific Meeting 2019. Brisbane, Queensland

45. Blazevski A, Scheltema MJ, Yuen B, Masand N, Haynes AM, Cusick T, Stricker P. Focal Irreversible Electroporation for Radiorecurrent Prostate Cancer – Update on Current Results and Establishment of the FIRE trial. TROG Annual Scientific Meeting 2019. Melbourne, Australia

46. Blazevski A, Scheltema MJ, Yuen B, Masand N, Haynes AM, Cusick T, Shnier R, Stricker P. Diagnostic accuracy of multiparametric magnetic resonance imaging to detect residual prostate cancer following focal therapy with irreversible electroporation. EAU 2019 – Annual Scientific Meeting – Barcelona.

47. Blazevski A, Scheltema MJ, Yuen B, Masand N, Haynes AM, Cusick T, Stricker P. Update on 12–month biopsy proven oncological and functional outcomes of primary irreversible electroporation for localised prostate cancer. EAU 2019 – Annual Scientific Meeting – Barcelona.

48. Blazevski A, Scheltema MJ, Yuen B, Masand N, Haynes AM, Cusick T, Stricker P. Salvage irreversible electroporation for locally recurrent prostate cancer after radiotherapy – Oncologic and functional outcomes. EAU 2019 – Annual Scientific Meeting – Barcelona.

49. Blazevski A, Scheltema MJ, Yuen B, Masand N, Haynes AM, Cusick T, Shnier R, Stricker P. Diagnostic accuracy of multiparametric magnetic resonance imaging to detect residual prostate cancer following focal therapy with irreversible electroporation. AUA 2019 – Annual Scientific Meeting – Chicago.

50. Blazevski A, Cusick T, Haynes AM, Stricker P. Evolution of Irreversible Electroporation into a prostate cancer treatment – From the laboratory to Urologists. AUA 2019 – Annual Scientific Meeting – Chicago.

51. Amin A, Blazevski A, Scheltema MJ, Stricker P, Thompson J. The MRI in active surveillance study (MRIAS): A prospective single arm cohort study replacing confirmatory biopsy with mpMRI in active surveillance for low risk prostate cancer – Asia–Pacific Prostate Cancer Conference 2019 – Melbourne, Australia.

52. Amin A, Blazevski A, Scheltema MJ, Thompson J, Stricker P. Salvage Radical Prostatectomy After Focal Irreversible Electroporation for Prostate Cancer: A Case Series Reporting Oncological Outcomes. Société International d’Urologie 2019 – Athens.

International and National Invited Surgeon

1993 – Malaysian Urological Society

1995 – Korean Urological Society

2000 – Chinese Urological Society

2008 – Western Australian Urological Society – Robot Assisted Radical Prostatectomy

2009 – Queensland Australian Urological Society – Robot Assisted Radical Prostatectomy

Invited Speaker

1992

Australasian Urological Society Annual Meeting – Intravesical BCG. "Immunotherapy & Chemotherapy – 10 year experience"

1993

Australasian Ultrasound Society – Annual Meeting

1.Transrectal ultrasound for prostate.

2. Penile Duplex ultrasound.

New Zealand Urological Society –"Transurethral needle ablation of the prostate". P.Stricker, G. Coombes.

Malaysian Urological Society – Incontinence & Collagen Implant

1994

International Urological Society – 23rd Congress

1. B.C.G. for Bladder cancer

2.Collagen for Stress Incontinence

3.TUNA for B.P.H.

8th Congress of World Ostomy Association – Adelaide."Sexual consequence of Surgery".

1996

Queensland Assert & Sexual Health Society Meeting. Specialised investigation of Impotence.

International Menopause Society

Symposium of male Sexual Dysfunction.

8th African Urological Society. Invited speaker "Peyronie's and side effects of injection treatment"

1997

South Australian Urological Society Meeting. Presentations on:

1.Role of Surgery for prostate cancer

2.Peyronie's Disease

3.Collagen Implant for Male Incontinence

South Africa Visiting Lecturer –"Peyronie's Disease & Injection Therapy

1998

Annual Urological Society of Australia Meeting – Adelaide. "Peyronie's Disease"

2000

Shanghai Urological Group – Shanghai China."1125 Brachytherapy for Prostate Cancer"

Asia–Pacific Urological Association Annual Meeting – Beijing China

– Brachytherapy for Prostate Cancer

– Prostate Cancer and Sexual Dysfunction

2001

Victorian State Urology Meeting. Presentations on:

– Brachytherapy

– Prostate Cancer

– Peyronie's Disease

– Grid Biopsy

Urological Society of Australasia (USA) – Annual Scientific Meeting

"Medico Legal Aspect of Prostate Cancer"

Australian Prostate Cancer Collaboration (APCC) ASM.

"Nomogram Validation for Prostate Cancer"

2002

Annual Australian Urological Meeting. Presentation on Prostate Cancer

NSW Urology Meeting. Presentation on Prostate Cancer.

National Prostate Cancer Symposium. Presentation on Prostate Cancer

2003

American Urological Association (AUA) Meeting – 2 presentations

Australian Annual Scientific Urology Meeting – 7 presentations

APCC – presentation on Prostate Cancer

Australian Brachytherapy Society –"Outcomes of High & Low Dose Brachytherapy"

Sloan Kettering Prostate Cancer Meeting – "Prostate Cancer Outcomes"

Eli Lilly Company Meeting –"Prostate Cancer & Erectile Dysfunction"

National Prostate Cancer Symposium –"Prostate Cancer & Surgery"

2004

Australian Brachytherapy Society – 2 presentations

Urological Society of Australasia – 2 presentations

Uro–Oncology Group of NSW – "Radical Prostatectomy"

Sydney University – Debate on Prostate Cancer

NSW Urology Meeting – 3 presentations

Australian–Israeli Chamber of Commerce – presentation on Prostate Cancer

2005

Australasian Urological Society – 2 presentations

Chinese Urological Society – 2 presenations

St Vincent's Hospital "Steggles" Conference

Brachytherapy Symposium – 4 presentations

Asia Pacific Uro–Oncology Meeting – presentation on "HIFU"

World Health Organisation Symposium Paris –Presentation on Prostate Cancer.

NSW Urological Society Meeting – 2 presentations

2006

Australasian Urological Society – 3 presentations

NSW Urological Society Meeting – 4 presentations

7th National Prostate Cancer Symposium Melbourne

Presentation on "HIFU"

2007

Australasian Urological Society – 2 presentations

General Practitioners Continuing Education Annual Meeting – 3 presentations

Urology Oncology Group Meeting – 2 presentations

2nd International Robotic Symposium Ohio – 1 presentation

PCFA Men's Health Promotion Forum – Prostate cancer treatment panel – radical prostatectomy (open, robotic & laparoscopic).

NSW Nurses Urological Society meeting – Topic: Prostate Cancer. October

2008

3rd International Robotic Symposium Orlando – 2 presentations. March

Laverty Pathology Men's Health Conference for GPs – Topic: Prostate Cancer.

Nurses Surgical Symposium Westmead Hospital – “Prostatectomy & Robotic Surgery”.

General Practitioner's Continuing Education Annual Meeting – Prostate cancer & PSA.

Prostate Cancer Foundation of Australia Hunter Region

Western Australian Urological Society National Annual Scientific Meeting –3 presentations.

Prostate Cancer Foundation of Australia 1st National Conference, Gold Coast "Future of Prostate Cancer".

2009

18th Australasian Brachytherapy Group Annual Scientific Meeting, Gold Coast –1 presentation.

Australasian Urological Annual Meeting. Gold Coast – 3 presentations

2010

Australasian Urological Society Annual Meeting Perth –2 presentations and debate: "Robotic Assisted Laparoscopic Radical Prostatectomy is the Gold Standard Surgical Treatment for Prostate Cancer".

5 ^th International Robotic Symposium Orlando. “Continence after robot radical prostatectomy”.

Integrative Medicine Society Meeting. “Integrative prostate cancer treatment” & “Robotics in prostate cancer surgery.”

11 ^th National Prostate Cancer Symposium Melbourne. August. “Continece post robotic radical prostatectomy”.

New Zealand Urological Meeting. “Prostate Cancer – How to choose” & “Robotic surgery”.

PCFA National Conference. “Prostate Cancer – How to choose” & “Side effects management”.

2011

NSW Section Urological Meeting, Sydney, November Point Counterpoint – Locally Advanced Prostate Cancer.

NSW Urological Nurses Conference, Sydney "How does one make a choice between different prostate cancer treatment modalities and robotic surgery".

12th Australasian Prostate Cancer Conference (APCC), Melbourne, August. Master class in robotic surgery.

Trainee Week 2011 "Localised Prostate Cancer – What We Do Know, What We Don’t". Factors in favour of robotic radical prostatectomy surgery.

General Practitioner Annual Symposium, Sydney, May.

1. Prostate cancer update

2. Benign prostatic hyperplasia update

The Inaugural international prostate cancer symposium – Weill Cornell Medical College New York.

1. Locally advanced prostate cancer

2. Benefits of robotic radical prostatectomy.

1. American Urological Society Annual Scientific Meeting. Washington, May.

1. Quality of Life

2. Transperineal biopsy of prostate

3. Locally advanced prostate cancer.

2012

GlaxoSmithKline Australia Pty Ltd GP Dinner, March. "STEP UP – Do more for your patients with BPH".

Friends of Israel Urological Symposium Tel Aviv May.

1. Learning curve of robot assist prostatectomy.

2. Nerve sparing radical prostatectomy – How do I do it –Bladder neck dissection and dissection of seminal vesicles.

1. NSW State Parliament Sydney. “Prostate cancer update”.

MRI of the Prostate – A Multidisciplinary Symposium. May. Sydney

1. The role of MRI

2. Screening and MRI

1. The Australian Vietnamese Health Professionals Association NSW Inc. – Annual Scientific Conference. October. Sydney. PSA & Prostate Cancer Update.

2013

1. 3rd Congress of Asian Pacific Prostate Society (APSS) – 13th April. Melbourne

“How to improve continence & potency after robot–assisted radical prostatectomy”.

1. St Vincent’s Campus Steggles Conference – April. Sydney

1. Focal therapy – Are we ready?

2. Biopsy techniques – TRUS v’s Transperineal

3. 2 live cases presentation (Nanoknife & HIFU)

2014

1. USANZ 67th Annual Scientific Meeting – The Role of MRI in the early detection of prostate cancer
2. Asia Pacific Imaging Meeting – The role of MRI
3. USANZ South Australian State Selection Meeting – Presentations on MRI & Focal Therapy
4. USANZ NSW State Section Meeting – Presentations on salvage radical prostatectomy, MRI, Nanoknife
5. Tolmar Lecture Series – Focal Therapy
6. CME GP Talk September – Prostate Cancer Update

2015

1. AUA New Orleans – May

1. BAUS/BJUI/USANZ – The Role of focal therapy in localized prostate cancer; preliminary Australian results

2. MRI Presentations

1. Cleveland Clinic & Case Western Reserve University Ohio – May

1. Transperineal biopsies

2. Focal Therapy

3. MRI

1. RANZCR NSW Branch Education Evening – An update of MRI in prostate cancer
2. NSW State Section Meeting – 7 ^th November

1. Focal therapy

2. Overview of prostate cancer imaging

1. Royal Australian College of Surgeons NSW – 10th November Graham Coupland Lecture – “The Challenge of Prostate Cancer Care – Past, Present & Future”

2016

1. USANZ Annual Scientific Meeting – MRI Education Course – Focal Therapy Debate
2. European Meeting EAU – Two papers on PSMA PET Scanning
3. Asian–Pacific Prostate Cancer Annual Meeting – New MRI Nomogram for Prostate Cancer
4. Israel FOPI International Meeting. Nanoknife Update, Surgery versus Radiation Debate, Robotic RP Technique
5. AUA. Focal Therapy – How to select
6. Webinar – Diet and Prostate Cancer

2017

1. USANZ 2017 – Focal therapy nanoknife and PSMA Imaging and MRI Imaging workshop
2. Robotic Symposium – Potency preservation in Robotics
3. PROSCA Portugal – Focal Nanoknife, Robotic RP
4. Tasmania ASM – Prostate Cancer Update
5. MRI Fusion Workshop – Co–convenor

2018

1. Hadassah Medical Center Jerusalem – Key note speaker for salvage prostate cancer treatment
2. Hadassah Hospital, Jerusalem – 3–week educational session and facility upgrading program. Work involved updating the robotic surgery program, nanoknife program, MRI–fusion program, brachytherapy program, multidisciplinary team, PSMA program, transperineal biopsy program and establishment of a link between Hadassah and St Vincent’s Hospital for research
3. Australasian Student’s Surgical Conference – Robotic surgery
4. National Robotic Symposium – Centralisation of robotic services
5. National Cancer Institute – Introduction of NanoKnife to Amsterdam
6. Netherlands Cancer Institute, Amsterdam – Operation of the DETECT probe for prostate cancer
7. Global Congress on Prostate Cancer, Frankfurt, Germany – PSMA screening and NanoKnife treatment
8. Friends of Israel Urology Symposium – Robotic Surgery, PSMA Screening and Nanoknife
9. 38th Congress of the Société Internationale d’Urologie, Seoul, Korea – Ideal framework for the introduction of Nanoknife – Presented on behalf of Professor Stricker by Urology Fellow Dr. Alexandar Blazevski

2019

1. 34 ^th Annual European Association of Urology Congress – Irreversible Electroporation (IRE) for Prostate Cancer – Presented on behalf of Professor Stricker by Urology Fellow Dr. Alexandar Blazevski
2. 27 ^th St Vincent’s Campus Research Symposium – Improving both oncologic and functional outcomes in prostate cancer via innovations in imaging, robotics and biomarkers – Presented on behalf of Professor Stricker by Dr. James Thompson

2020

International Society of Radiologists (ISMRM) – virtual conference, Aug 2020. Keynote address on the clinical role of MRI in Prostate Cancer. The ISMRM virtual conference was attended by approximately 10,000 people worldwide.

European Annual Scientific Urology Meeting (EAU20V)– virtual conference, Jul 2020. Invited presenter to discuss the results to date of both cancer clearance of the primary tumour, recurrence rates, side effect profile and salvage surgery. Prof Stricker’s conclusion was that the intermediate results are very encouraging with a remarkably low side effect profile and Nanoknife focal therapy a strong contender for being one of the major technologies to potentially treat focal prostate cancer internationally.EAU20V was attended by almost 10,000 delegates worldwide.

The World Society of Robotic Surgery (SRS)– virtual conference, Aug 2020. Invited speaker along with other major experienced robotic surgeons from the Sloan Kettering (New York) and University College Hospital in London among others in the area of salvage robotic surgery.A video presentation involving 10,000 delegates attending worldwide.

Australian Section of the World Society of Robotic Surgeons (SRS) – virtual conference, Aug 2020. Keynote speaker presenting a talk on preserving sexual function after robotic surgery as well as the management of high–risk prostate cancer. Prof Stricker’s presentation was part of an Asia Pacific Group of Expert Robotic Surgeons asked to describe his technique of potency preservation during Robotic Prostatectomy. He also gave a keynote address on high–risk prostate cancer. During this presentation, he made particular mention of the increasing role of PSMA PET scanning and described one of his most recent projects – the DETECT trial which is using a Geiger counter to help detect cancer which has spread to microscopic nodal disease and outside of the prostate during the operation of robotic surgery.

Professional Contributions

• Chief investigator of numerous pre–clinical and clinical research projects at St Vincent's Campus.
• In 1994 established the St Vincent's Prostate Cancer Clinical Database and Tissue Bank in conjunction with the Garvan Institute. These contain extensive clinical and pathological outcome data and have resulted in a comprehensive scientific and clinical source that has been acknowledged both nationally and internationally.
• Instigated the establishment of the St Vincent's Hospital Prostate Cancer Group.
• Education and mentoring of other Urologists, Urology Fellows and PHD, ILP, Honour students in the area of prostate cancer treatments and procedures.
• Reviewing of Prostate cancer grants for NHMRC
• Cancer Council "Localised Prostate Cancer" book – Member of review committee for both editions.
• "Your Guide to Prostate Cancer" by Dr Prem Rashid – Member of peer review group.
• Member of the Australian Cancer Network working party that developed guidelines for the Management of Localised & Advanced Prostate Cancer. This has been published and was the first evidence–based publication through the network. This was supported by the NHMRC.
• Regularly reviews manuscripts on prostatic conditions especially prostate cancer for peer reviewed journals including Medical Journal of Australia, Medicine Australia and Australian Prescriber.
• Research Supervisor for PhD/Masters students – Dr's David Quinn, Lisa Horvarth, Kris Rasiah, Ruban Thanigasalam, Kim Pryor, Andy Huo, James Symons, Richard Savdie and James Thompson.
• Supervisor of the Urology Fellow program at St Vincent's campus.
• Director of the Australian Prostate Cancer Collaboration – a body that co–ordinates prostate cancer research nationally.
• Co–author with Prof. Kerryn Phelps of the first national "PSA for the General Practitioner" book. This book was distributed to all GP's in Australia in 2004. An updated edition was written in 2008.
• Regular contributor to the "St Vincent's Clinic Proceedings" Magazine on new developments and treatments for prostatic conditions.
• Advisor to the NSW Cancer Council (book reviews).
• Member of PSA review board – PCFA & NHMRC.
• Contribution to the British Journal of Urology International e–learning modules for prostate cancer

Public Contributions

Prostate Cancer Support Network

1. Along with Jayne Matthews was involved in the initiation of the first prostate cancer support group in Australia at St Vincent's Hospital, Sydney. Has also been instrumental in the development of the Association of Prostate Cancer Support Groups throughout Australia and incorporating this in the Prostate Cancer Foundation of Australia.
2. Invited guest speaker at many prostate cancer support groups in NSW and ACT.
3. Guest speaker at the Inaugural NSW Men's Health Promotion Conference organised by the Prostate Cancer Foundation of Australia.

Public Education Information Brochures

1. Active member in an educational sense on prostate cancer issues through frequent contributions to newsletters, tapes/DVD's and a series of books. "Lifebuoy" – St Vincent's Campus prostate cancer support group newsletter and "Prostate News" – The Prostate Cancer Foundation of Australia.
2. AMA prostate cancer guidelines.
3. DVD for prostate cancer information for support groups (PCFA & personal).
4. Cancer Council booklet on Prostate cancer.

Television, Radio and Newspaper Interviews/Articles

1. Invited guest speaker on several community programs to discuss new developments in prostate cancer such as:

– Television: 60 Minutes–Channel 9, "What's Good for You",“A Current Affair” and Prime Time News on all TV stations.

– Radio: 2GB, John Laws, Dr John D'Arcy and ABC Radio national

– Newspapers: Financial Review and the Sydney Morning Herald

Website Service

1. Developed the official website for the St Vincent's Prostate Cancer Centre
2. www.prostate.com.au , & www.phillipstricker.com.au .
3. These sites are very informative, user friendly and offer a second opinion service.

General Practitioner Education

1. "PSA for the General Practitioner" – Co–author with Prof. Kerryn Phelps. This book was distributed to all G.P.'s throughout Australia.
2. GPCE (General Practitioner Continuing Education) Annual Conference – regular invited speaker at the National Conference for GP's held annually.
3. Invited guest speaker at numerous GP groups both in metropolitan and rural areas.
4. "Prostate Cancer for the General Practitioner" PSA Booklet Edition 2. Co–authored with Prof. Kerryn Phelps. This book was distributed to 21,500 GP's and Specialists throughout Australia (2008).

Prostate Cancer Foundation of Australia

1. Inaugural Director
2. Been integral in raising funds and establishing policy as a Foundation member of the organisation.
3. Contributed to the national "Be A Man" campaign to raise awareness of prostate cancer in the community.

Urology Nurses Education

1. Along with the nurses at St Vincent's Private Hospital, has constructed a diploma course in Urology, particularly in prostate cancer. This diploma course is now conducted annually.
2. Invited guest speaker at several NSW & Australian Urology Nurses Society conferences on prostate cancer treatments.

Post–doctoral Fellows, students (PHD, ILP and Honour) visiting Fellows Supervised

Michael Hoch (France)

Petr Macek (Czech Republic)

Ziv Maianski (Israel)

Ruban Thanigasalam

Can Huynh

Paul Chen

Carlo Yuen

Richard Savdie

Nicolas Doumerc (France)

James Symons (2012)

Tania Hossack (2012)

James Thompson (2012)

Lee Ponsky (USA) (2013)

Minh Tran (2014)

Pim Van Leeuwen (The Netherlands) (2015)

Francis Ting (2015)

Amila Siriwardana (2016)

Willamien van Den Bos (2016)

John Chang (2017)

James Thompson PhD (2017)

Anton Kalsbeek PhD (2015 – 2017)

Ilan Gielchinsky (Israel) (2017)

Matthijs Scheltema (The Netherlands) (2017)

Alexandar Blazevski (2018)

Brian Yuen (2018)

Amer Amin (2019)

William Gondoputro (2020)

Registrars Trained

Stuart Ehsman

Peter Nash

Graham Coombes

Justin Vass

Paul Kovac

Paul Gassner

Ramin Samali

Michael Wines

Hodo Hoximollo

Jim Adshead

Venu Chalasani

Charles Chabert

Can Huynh

Claire Whelan

Anthony Hutton